Method for measuring rubicon activity, method for measuring autophagy activity, and method for measuring degree of aging
By detecting age-related miRNAs in bodily fluids, the method simplifies the evaluation of Rubicon activity and autophagy activity, addressing the complexity and invasiveness of existing methods, enabling a reliable assessment of aging progression.
Patent Information
- Application Number
- PCT/JP2026/017251
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-04-30
- Publication Date
- 2026-11-12
AI Technical Summary
Current methods for measuring Rubicon activity and autophagy activity are complex and invasive, requiring the destruction of white blood cells to extract and quantify the Rubicon protein, making them unsuitable for a simple and non-invasive evaluation of aging progression.
A method involving the detection of age-related miRNAs, particularly those secreted via exosomes, such as hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486-5p, in bodily fluids like blood, serum, or urine, to assess Rubicon activity and autophagy activity, thereby evaluating aging progression.
Enables a non-invasive and rapid evaluation of Rubicon activity and autophagy activity, providing a simple means to assess aging progression through the use of miRNAs in easily collectible bodily fluids, improving efficiency and reliability of the measurement process.
Smart Images

Figure JP2026017251_12112026_PF_FP_ABST
Abstract
Description
Methods for measuring Rubicon activity, autophagy activity, and the progression of aging.
[0001] The present invention relates to a method for measuring Rubicon activity, autophagy activity, and aging, and more specifically, to a method for measuring Rubicon activity, autophagy activity, and the progression of aging by detecting or measuring the amount of miRNA.
[0002] Autophagy is responsible for the breakdown and recycling of intracellular substances, as well as the elimination of harmful substances that appear within cells (abnormal protein clumps, invading bacteria, damaged mitochondria, etc.). Autophagy contributes to the maintenance of healthy cells in various tissues. Autophagy is essential for the basic functions of cells in organs such as the lungs, kidneys, skin, and eyes, and exerts a protective effect on cells under conditions where these tissues are subjected to acute or chronic damage. Therefore, in these tissues, activating autophagy is an effective preventive and therapeutic method for diseases caused by autophagy deficiency (Non-Patent Literature 1).
[0003] On the other hand, Rubicon (Run domain Beclin-1 interacting and cysteine-rich containing protein) is known as a negative regulator of autophagy, inhibiting the autophagosome-lysosome fusion process.
[0004] Furthermore, Rubicon expression has been found to increase with aging in worm and mouse tissues. This suggests that the age-dependent increase in Rubicon weakens autophagy over time, thereby shortening the healthy lifespan of animals.
[0005] Rubicon is a key molecule in aging through the suppression of autophagy activity, and it is thought that targeting Rubicon may allow for the suppression of aging, the prevention, improvement, or treatment of age-related diseases or symptoms, or the extension of lifespan, as well as the assessment of the degree of aging, the risk of developing age-related diseases or symptoms, or the risk of shortened lifespan.
[0006] Since Rubicon is a negative regulator of autophagy, measuring the amount and activity of Rubicon makes it possible to measure or evaluate the activity of autophagy. Furthermore, given that decreased autophagy activity is suggested to be one of the major characteristics of aging, it becomes possible to assess the progression of aging.
[0007] However, measuring Rubicon required a complex method involving the destruction of white blood cells collected from the blood, and the extraction and quantification of the Rubicon protein contained within the white blood cells.
[0008] Therefore, there is a need for a simple method that can measure or evaluate the amount and activity of Rubicon, measure or evaluate autophagy activity, and measure or evaluate the progression of aging.
[0009] Autophagy in major human diseases. EMBO J. 2021 Oct 1;40(19):e108863. doi: 10.15252 / embj. 2021108863. Epub 2021 Aug 30. PMID: 34459017
[0010] Therefore, the present invention aims to provide a means that enables the measurement or evaluation of the amount and activity of Rubicon, the measurement or evaluation of autophagy activity, and the measurement or evaluation of the progression of aging in a simple manner.
[0011] The inventors of this invention discovered that Rubicon is involved in the secretion of exosomes related to aging and senescence, and in the increase of miRNAs that promote aging. Based on this discovery, the inventors found that by measuring miRNAs related to aging and senescence, it is possible to measure or evaluate the amount and activity of Rubicon, measure or evaluate autophagy activity, and measure or evaluate the progression of aging, thus completing the present invention.
[0012] In other words, the present invention is as follows: [1] A method for evaluating the amount or activity of Rubicon, characterized by comprising the step of detecting age-related miRNA in a sample. [2] A method for evaluating the amount or activity of Rubicon according to [1], wherein the age-related miRNA is a miRNA that increases with age. [3] A method for evaluating the amount or activity of Rubicon according to [1], wherein the age-related miRNA is a miRNA whose secretion to the extracellular space by exosomes increases with age. [4] A method for evaluating the amount or activity of Rubicon according to [1], wherein the age-related miRNA is a miRNA that targets FOXO-1 or EZH2. [5] The age-related miRNAs are human mature miRNAs (hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486-5p), and mouse mature miRNAs (mmu-miR-26a-5p, mmu-miR-10a-5p, m A method for evaluating the amount or activity of Rubicon [1], wherein one or more are selected from the group consisting of mu-miR-15b-5p, mu-miR-30e-3p, mu-miR-93-5p, mu-miR-191-5p, mu-miR-328-3p, mu-miR-486a-5p, mu-miR-486b-5p, mu-miR-1198-5p) (where the symbols of the RNAs indicate the registered names in the miRBase database). [6] A method for evaluating the amount or activity of Rubicon [1], wherein the sample is blood, serum, urine, or other bodily fluid. [7] A method for evaluating autophagy activity or the progression of aging, characterized by comprising a step of detecting age-related miRNAs in the sample. [8] A method for evaluating the autophagy activity or the degree of aging of the miRNA associated with aging, which is a miRNA that increases with age [7]. [9] A method for evaluating the autophagy activity or the degree of aging of the miRNA associated with aging, which is a miRNA that increases in secretion outside the cell by exosomes with age [7].
[10] A method for evaluating the autophagy activity or the progression of aging of the miRNAs associated with aging, wherein the miRNAs are miRNAs that target FOXO-1 or EZH2 [7].
[11] The miRNAs associated with aging are human mature miRNAs (hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486), and mouse mature miRNAs (mmu-miR-26a-5p, mm A method for evaluating autophagy activity or the progression of aging, wherein the sample is one or more selected from the group consisting of u-miR-10a-5p, mmu-miR-15b-5p, mmu-miR-30e-3p, mmu-miR-93-5p, mmu-miR-191-5p, mmu-miR-328-3p, mmu-miR-486a-5p, mmu-miR-486b-5p, mmu-miR-1198-5p) [7].
[12] A method for evaluating autophagy activity or the progression of aging, wherein the sample is blood, serum, or urine [7].
[0013] The present invention provides a means for measuring or evaluating the amount and activity of Rubicon, as well as measuring or evaluating autophagy activity or the progression of aging, in a simple manner.
[0014] This is a drawing showing an example of an embodiment of the present invention. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment. This is a drawing showing the results of the embodiment.
[0015] The present invention provides a method for evaluating the amount or activity of Rubicon, characterized by comprising a step of detecting age-related miRNAs in a sample. The sample refers to a biological sample collected from an animal such as a human or mammal, and examples include urine, blood, skin, hair, and serum, but urine, blood, and serum are preferred. The method of collecting these samples is not particularly limited.
[0016] It is preferable that the age-related miRNA is a miRNA whose volume increases with age. It is also preferable that the age-related miRNA is a miRNA whose secretion to the extracellular space by exosomes increases with age. Furthermore, it is preferable that the age-related miRNA is a miRNA whose molecular mechanism for secretion to the extracellular space with age and senescence is known, and which targets aging-suppressing genes such as FOXO-1 or EZH2.
[0017] In the present invention, suitable examples of miRNAs include human mature miRNAs (hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486-5p), and mouse mature miRNAs. miRNA (mmu-miR-26a-5p, mmu-miR-10a-5p, mmu-miR-15b-5p, mmu-miR-30e-3p, mmu-miR-93-5p, mm u-miR-191-5p, mmu-miR-328-3p, mmu-miR-486a-5p, mmu-miR-486b-5p, mmu-miR-1198-5p).
[0018] The method for detecting miRNA is not particularly limited, and known methods can be employed. For example, miRNA can be quantitatively detected by known methods such as RT-qPCR, microarrays, and next-generation sequencing.
[0019] The present invention provides a method for evaluating autophagy activity and the progression of aging, characterized by comprising a step of detecting age-related miRNAs in a sample. Since Rubicon is a negative regulator of autophagy, autophagy activity can be evaluated by measuring or evaluating the amount or activity of Rubicon. The sample and other components are the same as those used in the method for evaluating the amount or activity of Rubicon described above.
[0020] The configuration of the present invention will be described in more detail below.
[0021] The method of the present invention involves specific technical operations such as the physical detection or quantification of miRNA in a sample, and is not merely a description of natural laws or phenomena. That is, the present invention is configured as a method that includes specific steps such as (i) detecting or quantifying miRNA in a sample taken from a subject using predetermined primers and probes, and (ii) evaluating the amount or activity of Rubicon, autophagy activity, or the progression of aging based on the amount of miRNA detected or quantified. The method of the present invention provides a fundamentally different alternative technical means from conventional Rubicon measurement methods (such as methods that destroy leukocytes and directly quantify the Rubicon protein), and requires a series of specific and tangible operations such as sample pretreatment, nucleic acid extraction, reverse transcription reaction, amplification reaction, and signal detection.
[0022] The evaluation method of the present invention preferably includes a practical application that enables the selection of specific intervention measures for a subject based on the evaluation results. For example, if a decrease in autophagy activity in a subject is detected by the method of the present invention, it is preferable to provide information that will help in the selection of specific improvement measures, including dietary therapy, exercise therapy, supplement intake, or drug therapy, as described later. Furthermore, if the degree of aging is evaluated to be high, it is preferable to propose specific preventive interventions, such as the administration of an autophagy activator, the implementation of calorie restriction, or the initiation of a specific exercise program. In this way, the method of the present invention makes it possible to generate information for improving the physiological state of a subject.
[0023] Furthermore, the present invention provides a technical improvement over the prior art. Conventional methods for evaluating Rubicon activity required an invasive and cumbersome procedure of extracting proteins from leukocytes. In contrast, the method of the present invention enables non-invasive and rapid evaluation of Rubicon activity by using miRNA in easily collectible bodily fluids such as blood, serum, or urine as an indicator. This technical improvement is based on the inventors' knowledge that miRNA is secreted extracellularly via exosomes and exists relatively stably in bodily fluids, thereby improving the efficiency and reliability of the measurement process itself. <Sample Preparation>
[0024] The samples used in the present invention are biological samples collected from subjects, and include, for example, blood (whole blood, peripheral blood), serum, plasma, urine, saliva, tears, cerebrospinal fluid, synovial fluid, amniotic fluid, or other body fluids. These samples can be obtained by conventional blood collection procedures for blood, by collecting random or early morning urine for urine, and by spontaneous or stimulated secretion for saliva. Sample collection is preferably performed by non-invasive or minimally invasive methods.
[0025] When detecting miRNA from serum or plasma samples, it is preferable to extract miRNA from exosomes in the sample. Methods for separating exosomes include ultracentrifugation, polymer precipitation (e.g., ExoQuick reagent), size exclusion chromatography, magnetic bead method (e.g., MagCapture Exosome Isolation Kit PS), and affinity purification. For RNA extraction from separated exosomes, it is preferable to use a commercially available kit optimized for miRNA extraction (e.g., miRNeasy Serum / Plasma Kit, ISOGEN II, etc.). In the examples of the present invention, ExoQuick reagent and MagCapture Exosome Isolation Kit PS Ver. 2 were preferably used for separating exosomes from serum. When detecting miRNA from a urine sample, since exosomes in urine are relatively stable, it is preferable to remove cellular components by centrifugation immediately after collection and separate the exosomes from the supernatant. <miRNA detection>
[0026] In the present invention, the detection of miRNA refers to confirming the presence or amount of a target miRNA present in a sample by physical, chemical, or biochemical means. The method for detecting miRNA is not particularly limited, but preferred methods include reverse transcription quantitative polymerase chain reaction (RT-qPCR), digital PCR, microarray, next-generation sequencing (NGS), isothermal amplification, Northern blotting, and in situ hybridization. These methods may be used individually or in combination.
[0027] The detection and quantification of miRNA using RT-qPCR preferably includes the following steps. First, RNA is extracted from the sample. The RNA extraction method is not particularly limited, but the phenol-chloroform method, silica column method, or magnetic bead method is preferably used. For miRNA extraction from serum or plasma, it is preferable to include exosome lysis. Next, a reverse transcription reaction is performed using the extracted RNA as a template to synthesize cDNA. Since miRNA is a short-chain RNA with a length of 21 to 25 nucleotides, it is preferable to use the stem-loop primer method or the poly-A tail method for reverse transcription. In the examples of the present invention, reverse transcription using the TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher Scientific) is preferably used. Subsequently, quantitative PCR is performed using the synthesized cDNA as a template. For quantitative PCR, for example, the TaqMan probe method or the SYBR Green method is used. Specific primers and probes for the target miRNA can be selected from commercially available assay kits or designed based on known miRNA sequence information.
[0028] In quantification by RT-qPCR, it is preferable to use a stably expressed small RNA such as RNU6 or miR-16-5p as an internal control. The expression level of the target miRNA can be calculated, for example, by the ΔΔCt method or the ΔCt method. Specifically, the ΔCt value is calculated by subtracting the Ct value of the internal control from the Ct value of each target miRNA, and then the ΔΔCt value, which is the difference from the ΔCt value of the control group, is calculated, and the relative expression level can be determined as 2^(-ΔΔCt). When performing absolute quantification, it is preferable to create a calibration curve using synthetic miRNA of known concentration and calculate the concentration of the target miRNA in the sample (copy number / μL, etc.).
[0029] The quantification of miRNA using digital PCR has the advantage of enabling absolute quantification without the need for a standard curve, compared to RT-qPCR. In digital PCR, for example, a cDNA sample after reverse transcription is distributed into small compartments (droplets or chambers), PCR amplification is performed in each compartment, and the absolute copy number of the target miRNA is calculated based on the Poisson distribution from the proportion of positive compartments. This method is particularly suitable for highly sensitive and accurate quantification of miRNA from minute amounts of sample.
[0030] The detection of miRNAs using microarrays has the advantage of being able to comprehensively detect multiple miRNAs simultaneously. In microarrays, for example, miRNAs extracted from a sample are fluorescently labeled and hybridized to miRNA-specific probes immobilized on a substrate, and the expression level of the miRNAs is measured from the intensity of the fluorescence signal. In the present invention, when using microarrays, it is preferable to use an array that includes probes for at least one of the miRNAs listed in Table 1. By simultaneously obtaining expression profiles of multiple miRNAs, it becomes possible to evaluate the amount or activity of Rubicon, autophagy activity, or the progression of aging with greater accuracy.
[0031] The detection and quantification of miRNAs using next-generation sequencing (NGS) has the advantage of enabling the identification of novel miRNAs in addition to the quantification of known miRNAs. In the NGS method, for example, a library is prepared from small RNAs extracted from a sample, ultra-parallel sequencing is performed, the obtained reads are mapped to a reference genome or miRNA database (such as miRBase), and the read count for each miRNA is calculated. For normalization of the read count, statistical methods such as the RPM (reads per million) method or the DESeq2 method are preferably used. In the examples of the present invention, small RNA sequencing was performed by BGI, and small RNAs of 18 to 30 nucleotides in length were separated by gel electrophoresis. A library was then prepared using the MGIEasy Small RNA Library Prep Kit, and sequencing was performed using a DNBSEC-G400 instrument. <Example of a workflow from miRNA detection to evaluation of Rubicon quantity or activity>
[0032] An example of the specific procedure for evaluating the amount or activity of Rubicon in the present invention, from the detection or quantification of miRNA to the evaluation of the amount or activity of Rubicon, is described below.
[0033] The first step is to collect a sample from the subject. The sample is preferably blood, serum, plasma, or urine. After sample collection, exosome separation and RNA extraction are performed as needed.
[0034] The second step involves detecting or quantifying age-related miRNAs in the sample. Preferably, the miRNAs to be detected are one or more selected from the group listed in Table 1, i.e., in the case of humans, hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486-5p. Examples have confirmed that these miRNAs are secreted into exosomes in a Rubicon-dependent manner with age. In particular, hsa-miR-26a-5p and hsa-miR-486-5p are miRNAs that target FOXO-1 or EZH2, and have been confirmed to have the function of promoting cellular senescence. Therefore, the detection or quantification of these miRNAs has high utility as biomarkers that reflect the amount or activity of Rubicon.
[0035] As a third step, the amount or activity of Rubicon is evaluated based on the amount of miRNA detected or quantified. This evaluation is based on the following principle: Rubicon recruits WIPI2 and WIPI3 to endosomes and promotes exosome biosynthesis via the ESCRT mechanism. An increase in the amount or activity of Rubicon leads to an increase in exosome secretion, and consequently, an increase in the extracellular release of age-related miRNA contained in the exosomes. Therefore, the amount of age-related miRNA in the sample serves as an indirect indicator of the amount or activity of Rubicon.
[0036] As a specific evaluation criterion, the amount of target miRNA in the subject's sample is compared to the control. The control can be (i) past measurements of the same subject, (ii) reference values (reference ranges) for age-specific healthy populations, or (iii) average values for young subject groups. If the amount of target miRNA is significantly increased compared to the control, it can be evaluated that the subject's Rubicon quantity or activity has increased. It is preferable to improve the accuracy of the evaluation by simultaneously measuring multiple miRNA species and comprehensively evaluating their results. For example, if both hsa-miR-26a-5p and hsa-miR-486-5p are more than twice the control value, it can be determined that there is a significant increase in Rubicon activity. <Example of the flow from miRNA detection to evaluation of autophagy activity or aging progression>
[0037] The following describes an example of the specific procedure from the detection or quantification of miRNA to the evaluation in the method for evaluating autophagy activity or the progression of aging according to the present invention.
[0038] The steps for sample collection and detection or quantification of miRNA are the same as those for evaluating the amount or activity of Rubicon described above. Specifically, exosomes are separated from samples such as blood, serum, plasma, or urine collected from subjects, miRNA is extracted, and then the miRNA is detected or quantified by methods such as RT-qPCR, digital PCR, microarray, or NGS.
[0039] The evaluation of autophagy activity is based on the following principle: Rubicon is a negative regulator of autophagy and inhibits the fusion process between autophagosomes and lysosomes. When the amount or activity of Rubicon increases, autophagy activity decreases, and when the amount or activity of Rubicon decreases, autophagy activity increases. Therefore, if an increase in the amount or activity of Rubicon is shown by the above method (i.e., an increase in aging-related miRNA is detected), the subject's autophagy activity can be evaluated as decreased. Conversely, if the amount of aging-related miRNA is at or below the control level, the subject's autophagy activity can be evaluated as maintained.
[0040] The evaluation of the progression degree of aging is based on the following principle. A decrease in autophagy activity is one of the main characteristics of aging, and the accumulation of Rubicon with aging reduces autophagy activity over time, thereby shortening healthy life expectancy. Furthermore, miRNAs (particularly miR-26a-5p and miR-486a-5p) in exosomes secreted accompanying the accumulation of Rubicon target and suppress anti-aging genes such as FOXO1 and EZH2, and exert a paracrine effect that promotes cellular senescence even in adjacent cells. Therefore, the amount of aging-related miRNA in a sample serves as a direct indicator of the progression degree of aging in a subject.
[0041] In the evaluation of the progression degree of aging, by comparing the amount of target miRNA with the reference range of a healthy population of the same age, it is possible to determine whether the biological age of the subject is advanced, equivalent, or delayed compared to the chronological age. For example, if the aging-related miRNA profile of a subject falls within the reference range of an age group higher than the chronological age, the aging of the subject is evaluated to be advanced compared to the chronological age. Such evaluation results provide objective information for determining the necessity and urgency of preventive intervention for the subject. <Improvement Method Based on Evaluation Results of Autophagy Activity>
[0042] In one aspect of the present invention, specific means for improving autophagy activity can be proposed to a subject based on the evaluation results of autophagy activity. For subjects in whom a decrease in autophagy activity is detected, it is preferable to select and propose appropriate means according to the subject's condition from comprehensive improvement measures including diet / nutrition intervention, exercise intervention, drug / supplement intervention, and lifestyle improvement described below.
[0043] (Dietary and Nutritional Interventions) Dietary interventions to improve autophagy activity include calorie restriction, intermittent fasting, and intake of specific nutrients. Caloric restriction is a dietary method that reduces total calorie intake to the extent that it does not cause nutritional deficiencies, and is known to activate autophagy through the suppression of mTOR (mammalian target of rapamycin) signaling. Specifically, it is preferable to restrict the total daily calorie intake to about 70-80% of the normal amount. Intermittent fasting is a dietary pattern that includes periods of fasting for a certain amount of time, and is preferably implemented by alternating between a 16-hour fast and an 8-hour feeding window (16:8 method), or by having two low-calorie days per week (5:2 method). Intermittent fasting promotes autophagy through the activation of AMPK (AMP-activated protein kinase) and the suppression of mTOR.
[0044] Examples of food components that activate autophagy include spermidine, resveratrol, curcumin, EGCG (epigallocatechin gallate), and oleuropein. Spermidine is a polyamine found in wheat germ, soybeans, aged cheese, mushrooms, etc., and induces autophagy through inhibition of acetyltransferase. Resveratrol is a polyphenol found in red wine, grape skins, peanuts, etc., and promotes autophagy through activation of SIRT1 (sirtuin 1). Curcumin is a polyphenol found in turmeric and induces autophagy through inhibition of mTOR and increased expression of Beclin-1. EGCG is a catechin found in green tea and promotes autophagy through inhibition of mTOR and activation of AMPK. Oleuropein is a phenolic compound found in olives and olive oil and promotes autophagy through activation of AMPK. These food components can be consumed by eating the food itself or as supplements.
[0045] (Exercise Intervention) Exercise is one of the effective means of activating autophagy. In particular, aerobic exercise has been reported to activate autophagy in tissues such as skeletal muscle, liver, and heart. For exercise programs aimed at improving autophagy activity, it is preferable to perform moderate-intensity sustained aerobic exercise (walking, jogging, swimming, cycling, etc.) 3 to 5 times a week for 30 to 60 minutes each time. The intensity of the exercise is preferably in the range of 60 to 70% of the maximum heart rate. High-intensity interval training (HIIT) is also suitable as an exercise method that efficiently activates autophagy in a short time. HIIT is a training method that alternates between high-intensity exercise (e.g., 85 to 95% of the maximum heart rate) and low-intensity recovery periods. For example, a protocol that repeats 30 seconds of all-out sprints and 60 seconds of light jogging 8 to 10 times is an example. Resistance training (strength training) has also been reported to contribute to the activation of autophagy in skeletal muscle.
[0046] (Drug and Supplement Intervention) Examples of drugs or supplements that activate autophagy include the following: Rapamycin (sirolimus) is a macrolide immunosuppressant that directly inhibits mTOR and has a potent autophagy-inducing effect. However, it has side effects such as immunosuppression, so it must be used under the supervision of a physician. Metformin is a biguanide diabetes drug that promotes autophagy through the activation of AMPK. Lithium induces autophagy independently of mTOR by inhibiting inositol monophosphatase. Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are precursors of NAD+ and contribute to the activation of sirtuin-mediated autophagy. Uroritin A is a metabolite of ellagic acid produced by intestinal bacteria and has been reported to activate mitophagy (mitochondrial-selective autophagy).
[0047] (Lifestyle Improvement) Lifestyle improvements to maintain or improve autophagy activity include ensuring sufficient sleep, managing stress, and maintaining an appropriate weight. Autophagy has been reported to be activated during sleep, so it is preferable to ensure 7 to 9 hours of high-quality sleep per day. Chronic stress is known to suppress autophagy through an increase in cortisol levels, so it is preferable to incorporate stress management techniques such as meditation, yoga, and deep breathing. In addition, excessive obesity suppresses autophagy through the sustained activation of mTOR signaling, so it is preferable to maintain an appropriate body mass index (BMI).
[0048] In one embodiment of the present invention, after implementing the above-described means for improving autophagy activity, the evaluation method of the present invention can be performed again after a predetermined period (e.g., 1 month, 3 months, 6 months, or 12 months) has elapsed, and the effect of the improvement means can be monitored by measuring the change in the amount of aging-related miRNA. If the amount of aging-related miRNA is decreasing, it can be determined that the improvement means being implemented is effective. If there is no change or it is increasing, it can be determined that the improvement means need to be reviewed or strengthened. Such monitoring makes it possible to formulate an autophagy activity improvement program optimized for each individual subject. <Improvement method based on evaluation results of the degree of aging progression>
[0049] In one embodiment of the present invention, specific means for suppressing the progression of aging can be proposed to subjects based on the results of an evaluation of the degree of aging progression. For subjects evaluated as having a high degree of aging progression, in addition to improving autophagy activity, a comprehensive anti-aging strategy may be proposed that includes, for example, suppression of the paracrine effect of senescent miRNAs, removal of senescent cells (senolysis), and organ / tissue-specific anti-aging interventions.
[0050] In one embodiment of the present invention, after implementing measures to improve the progression of aging, the evaluation method of the present invention is performed again after a predetermined period (e.g., 3 months, 6 months, or 12 months) has elapsed, and the effectiveness of the implemented improvement measures can be monitored over time by tracking changes in the amount of aging-related miRNA. This iterative evaluation and feedback cycle makes it possible to construct a personalized anti-aging program optimized for each subject. <Evaluation System>
[0051] In one embodiment of the present invention, the steps of detecting or quantifying miRNA, evaluating the amount or activity of Rubicon, evaluating autophagy activity or the degree of aging progression, and proposing improvements based on the evaluation results can be performed by a computer system (hereinafter also referred to as the "evaluation system") comprising one or more processors, memory, and a communication interface. The evaluation system comprises, for example, at least a data input unit, an analysis processing unit, an evaluation unit, an improvement proposal unit, and an output unit. Each of these units may be configured as a functional module realized by the processor executing a program stored in memory or a storage device, as a dedicated hardware circuit, or as a combination thereof.
[0052] (Data Input Unit) The data input unit has the function of receiving measurement data output from the miRNA measuring device, converting it into a data format that can be processed by the subsequent analysis processing unit, and storing it. The data input unit includes an interface circuit connected to the miRNA measuring device via wired communication (USB, RS-232C, Ethernet, etc.) or wireless communication (Wi-Fi, Bluetooth, etc.), and a buffer memory for temporarily storing the received measurement data.
[0053] The type of measurement data received by the data input unit varies depending on the miRNA detection method used. In the case of RT-qPCR or digital PCR, the measurement data consists of time-series data of fluorescence signals including Ct values (threhold cycle values) or Cq values (quantification cycle values) corresponding to each target miRNA and internal control, or the number of positive compartments and total compartments in the digital PCR method. In the case of microarray, the measurement data consists of array data of fluorescence intensity values corresponding to each probe spot. In the case of NGS, the measurement data consists of sequence data including read counts mapped to each miRNA species. In addition to this measurement data, the data input unit stores in memory the subject's identification information (anonymized ID), sample type (serum, plasma, urine, etc.), date and time of sample collection, and identification information of the measurement protocol used.
[0054] Preferably, the data input unit also has a function to accept subject attribute information. Subject attribute information includes age (date of birth), sex, height, weight, body mass index (BMI), medical history, medications currently being taken, lifestyle (eating patterns, exercise frequency, sleep duration, alcohol consumption, smoking history, etc.), and past measurement history. This attribute information is used to generate individualized evaluations and suggestions in the subsequent evaluation unit and improvement suggestion unit. Attribute information can be entered by means of a keyboard, touchscreen, voice input, or optical character recognition (OCR) of a questionnaire using a camera. It is also possible to automatically acquire attribute information through data linkage with an electronic medical record system or health management application.
[0055] (Analysis Processing Unit) The analysis processing unit has the function of performing preprocessing, normalization, and quantitative calculations on the measurement data received from the data input unit, and calculating the expression level of each target miRNA. The analysis processing unit includes a processor, a program memory in which the analysis algorithm is stored, and a working memory used for calculations.
[0056] Preprocessing in the analysis processing unit includes quality check of the measurement data. In quality check, the following are verified: (i) whether the Ct value of the internal control (Rnu6 or miR-16-5p, etc.) is within a preset tolerance range; (ii) whether the signal of the negative control (NTC: no-template control) is below a threshold; (iii) whether the coefficient of variation (CV value) between technical iterations is within an tolerance range (preferably CV < 10%); and (iv) whether the shape of the amplification curve is normal. If the quality check reveals that measurement data does not meet any of the criteria, the analysis processing unit either flags the data and displays a warning on the output unit, or executes a process to exclude the data from analysis.
[0057] Normalization in the analysis processing unit is a process to correct for systematic variability between samples. In the case of RT-qPCR, the ΔCt value is calculated by subtracting the Ct value of the internal control from the Ct value of each target miRNA (ΔCt = Ct_target - Ct_reference). Furthermore, the ΔΔCt value is calculated as the difference from the mean ΔCt of the control group (ΔΔCt = ΔCt_sample - ΔCt_control), and the relative expression level is calculated as 2^(-ΔΔCt). In the case of digital PCR, the absolute copy number based on the Poisson distribution is calculated from the proportion of positive compartments and converted to the copy number per input RNA amount or sample volume. In the case of microarray methods, normalization is performed using quantile normalization or robust multi-array mean (RMA) method. In the case of the NGS method, RPM normalization based on total read count or DESeq2 size factor normalization is performed. The analysis processing unit automatically selects and applies the appropriate normalization method from among these methods depending on the measurement method used.
[0058] (Evaluation Unit) The evaluation unit has the function of calculating the subject's Rubicon quantity or activity score, autophagy activity score, and aging progression score (hereinafter collectively referred to as "evaluation score") based on the expression level or composite score of each miRNA received from the analysis processing unit. The evaluation unit includes a processor and a memory that stores an evaluation algorithm and a reference database.
[0059] The evaluation unit includes a reference database. The reference database stores reference ranges (reference values) for the expression levels of each miRNA in a healthy population, classified by age group (e.g., 20s, 30s, 40s, 50s, 60s, 70s, and 80s and older), sex, and sample type. Preferably, the reference ranges are stored as median, interquartile range, and percentile values (5th percentile, 25th percentile, 50th percentile, 75th percentile, and 95th percentile) for each classification group. Preferably, the reference database is constructed based on data obtained from clinical research or large-scale cohort studies and is updated regularly as new data accumulates.
[0060] The evaluation of Rubicon quantity or activity in the evaluation unit is performed, for example, by following these steps: First, the subject's miRNA expression level (or composite score) is compared with the reference range for the same age group and sex stored in the reference database. Next, the unit calculates which percentile of the reference range the subject's measurement falls on and quantifies it as a Rubicon activity score. For example, if the subject's measurement exceeds the 75th percentile of the reference range, Rubicon activity is categorized as "slightly high"; if it exceeds the 90th percentile, it is categorized as "high"; and if it exceeds the 95th percentile, it is categorized as "very high." The evaluation unit outputs both a continuous score based on percentiles (a score in the range of 0 to 100, etc.) and a category classification (normal, slightly high, high, very high, etc.).
[0061] The evaluation unit assesses autophagy activity by scaling inversely based on the amount or activity score of Rubicon. That is, since Rubicon is a negative regulator of autophagy, a higher Rubicon activity score results in a lower autophagy activity score. The evaluation unit takes the Rubicon activity score as input and applies a predefined transformation function (e.g., linear transformation, logarithmic transformation, or sigmoid transformation) to calculate the autophagy activity score. The parameters of the transformation function are predetermined based on the correlation between Rubicon expression level and indicators of autophagy activity (e.g., LC3-II / LC3-I ratio, p62 degradation rate, etc.).
[0062] The assessment of the progression of aging in the evaluation unit is performed in two stages, for example. In the first stage, the subject's miRNA expression profile (a combination of expression levels of multiple miRNA species) is compared with the reference profile for each age group, and the age group in which the subject's profile is most similar is estimated as the "biological age." Euclidean distance, Mahalanobis distance, or cosine similarity can be used to calculate the similarity. Alternatively, a pre-built regression model (e.g., ElasticNet regression or neural network regression) can be applied, and the biological age can be predicted as a continuous value using miRNA expression levels as input. In the second stage, the difference between the estimated biological age and the subject's chronological age (biological age - chronological age) is calculated and used as the aging progression score. If the difference is a positive value (i.e., biological age is greater than chronological age), aging is evaluated as progressing relative to chronological age; if the difference is a negative value, aging is evaluated as lagging relative to chronological age.
[0063] Preferably, the evaluation unit also has a risk stratification function. The risk stratification function, for example, combines the Rubicon activity score, autophagy activity score, and aging progression score to classify subjects into multiple risk categories (e.g., four levels: low risk, medium risk, high risk, and very high risk). To determine the risk category, rule-based classification based on thresholds for each score, or classification using machine learning models (logistic regression, random forest, etc.) can be used. The risk category is used in the subsequent improvement suggestion unit as a criterion for determining the type and intensity of recommended improvement measures.
[0064] (Improvement Proposal Unit) The Improvement Proposal Unit has the function of selecting specific improvement measures for the subject and generating an improvement proposal report based on the evaluation score and risk category received from the Evaluation Unit. The Improvement Proposal Unit preferably includes a processor, an improvement measures database, and a memory storing a proposal generation algorithm.
[0065] The Improvement Methods Database systematically stores information on improvement methods considered effective in improving autophagy activity and suppressing the progression of aging. The information stored in the Improvement Methods Database includes the type of improvement method (categories such as dietary / nutritional intervention, exercise intervention, supplement intervention, drug intervention, and lifestyle modification), the specific implementation method for each improvement method, the expected degree of effect, application conditions (applicability based on age, BMI, medical history, etc.), contraindications (contraindications for subjects with specific diseases, etc.), the level of evidence (quality of evidence such as randomized controlled trials, cohort studies, case-control studies, and expert opinions), and the recommended duration and dosage. It is preferable that the Improvement Methods Database be updated regularly in accordance with the publication of new research results.
[0066] The suggestion generation algorithm generates improvement suggestions using the following steps: First, it extracts candidate improvement measures from the improvement measures database according to the risk category received from the evaluation unit. For low risk, the focus is on dietary and nutritional interventions and lifestyle modifications; for medium risk, these are supplemented with exercise and supplement interventions; and for high risk or higher, drug interventions are also considered. Second, based on the subject's attribute information (age, sex, BMI, medical history, medications taken, etc.) obtained through the data input unit, improvement measures that fall under contraindications are excluded from the candidates. For example, the suggestion of rapamycin is excluded for subjects receiving immunosuppressive therapy, and a note regarding consistency with existing prescriptions is added to the suggestion of metformin for subjects already taking diabetes medication. Third, from the remaining candidates, improvement measures with a high level of evidence and a large expected degree of effect are selected preferentially, and a prioritized list of improvement suggestions is generated.
[0067] The improvement suggestion unit outputs the generated improvement suggestions as a structured improvement suggestion report. Preferably, the improvement suggestion report includes (i) a summary of the subject's evaluation results (each score and risk category), (ii) a list of recommended improvement measures (in order of priority, including specific implementation methods and expected effects for each measure), (iii) a recommended timing for the next evaluation, and (iv) a note recommending consultation with a healthcare professional. In particular, if the improvement measures include drug interventions, a warning should be added stating that they must be implemented under the supervision of a physician.
[0068] The improvement suggestion unit preferably has a function to track the effects of improvements over time. The tracking function compares the changes in the past evaluation scores of the same subject with information on the improvement measures implemented at each point in time, and estimates the individual effects of each improvement measure. Specifically, it statistically analyzes the score changes before and after the initiation of a particular improvement measure and evaluates the effectiveness of that improvement measure for each subject. These tracking results are reflected in the optimization of subsequent improvement suggestions. That is, improvement measures that have been shown to be effective in the past are recommended with a higher priority, and improvement measures that have not been shown to be effective are replaced with alternative measures. This feedback loop enables the continuous refinement of the individualized improvement program optimized for each subject.
[0069] (Output Unit) The output unit has the function of displaying or transmitting evaluation results from the evaluation unit and improvement proposal reports from the improvement proposal unit in a format that can be viewed by the user (subject, medical professional, or researcher). Preferably, the output unit includes a display device (display, touchscreen, etc.), a printing device (printer, etc.), and a data transmission unit (network interface, email transmission module, etc.). <One embodiment of the overall configuration of the evaluation system>
[0070] In one embodiment of the present invention, the above evaluation system can be configured as a standalone evaluation device. The evaluation device comprises a housing, a processor (CPU, GPU, or a combination thereof) located within the housing, memory (RAM and ROM or flash memory), storage (SSD or HDD), a communication interface (wired LAN port, wireless LAN module, USB port, Bluetooth module, etc.), an input device (keyboard, mouse, touchscreen, barcode reader, etc.), and a display device (liquid crystal display or organic EL display). The processor reads the evaluation program stored in the storage into the memory and executes it, thereby realizing the functions of the data input unit, analysis processing unit, evaluation unit, improvement suggestion unit, and output unit described above.
[0071] The evaluation device may be configured to be used integrally with or directly connected to the miRNA measurement device. In this case, the communication interface of the evaluation device is connected to the output port of the miRNA measurement device (RT-qPCR device, digital PCR device, microarray scanner, or NGS sequencer), and the measurement data is automatically transferred to the evaluation device after the measurement is completed. Upon detecting the receipt of the measurement data, the evaluation device automatically performs analysis processing, evaluation, and generation of improvement suggestions, and displays the results on a display device. This configuration makes it possible to efficiently perform a series of steps from miRNA measurement to obtaining evaluation results with minimal manual work by the user.
[0072] As another embodiment of the evaluation device, the evaluation device may be configured as a point-of-care (POC) type portable device. The portable evaluation device comprises a small housing, an embedded processor (such as an ARM-based processor), a touchscreen, a battery, and a simple miRNA measurement module (such as a cartridge-type module using isothermal amplification). The portable evaluation device detects miRNA from a cartridge into which a sample has been inserted, performs analysis and evaluation using the processor within the device, and displays the results on the touchscreen. The portable evaluation device can be used in clinics, pharmacies, health checkup facilities, or the subjects' homes without requiring specialized equipment. Preferably, the portable evaluation device has a function to transmit measurement results to a server described later via a wireless communication module. <Server Configuration>
[0073] In one embodiment of the present invention, the evaluation system described above can be configured as a client-server type system consisting of a server and client terminals connected via a network. In this embodiment, at least a portion of the analysis processing unit, evaluation unit, and improvement proposal unit are executed on the server side, and the client terminals function as data input and output units. <Configuration of the evaluation kit>
[0074] In one aspect of the present invention, a kit for carrying out the above evaluation method is provided. The kit preferably includes primers and / or probes for detecting a target miRNA. The primers and / or probes included in the kit preferably target one or more miRNAs selected from the group consisting of hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486-5p. The kit may further include reverse transcriptase, polymerase for PCR, dNTP mixture, reaction buffer, internal control primers and probes (for Rnu6 or miR-16-5p), synthetic miRNA for positive control, RNA extraction reagent, and / or exosome isolation reagent. The kit may include an access code or license key for accessing the evaluation device or server. Users of the kit can measure miRNA using the kit and upload the obtained measurement data to the evaluation device or server to obtain evaluation results and improvement suggestions for Rubicon quantity or activity, autophagy activity, or the progression of aging.
[0075] [Experimental Procedure] This study was conducted in compliance with all relevant ethical guidelines. Animal experiments were approved by the Osaka University Animal Experiment Committee and conducted in accordance with Japan's "Act on Welfare and Management of Animals (No. 25)".
[0076] Cell cultures: hMSCs (human mesenchymal stem cells): Obtained from Lonza. HEK293T cells: Obtained from American Type Culture Collection (ATCC). HeLa Kyoto cells and RPE-1 cells: The same as those previously used in this laboratory (References 62, 80, 81). Rubicon KO MEF (mouse embryonic fibroblasts) and RUBCN KO HeLa Kyoto cells: Previously produced in this laboratory (References 21, 80). Atg16l1 KO MEF: Produced in collaboration with S. Akira of Osaka University (Reference 82). Fip200 KO MEF: Previously reported (Reference 83). - Atg2A KO / Atg2B KO (Atg2 KO) MEF, Atg5 KO MEF, Atg14 KO MEF: Provided by N. Mizushima of the University of Tokyo. - Beclin-1 KO MEF and Uvrag KO MEF: Provided by S. Akira of Osaka University. - WIPI2 KO MEF: Provided by S. Shimizu of Tokyo Medical and Dental University (Reference 84). - Plat-E cells: Provided by T. Kitamura of the University of Tokyo (Reference 85). - IMR90 cells: Provided by A. T. of the Cancer Institute.
[0077] Culture conditions: MEF, HEK293T, HeLa Kyoto, Plat-E, IMR90, and RPE-1 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Sigma-Aldrich, D6046) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. MSCs were cultured in Mesenchymal Stem Cell Growth Medium 2 (PromoCell, C-28009) supplemented with 1% penicillin-streptomycin. - RPE-1 cells were treated with doxorubicin (FUJIFILM Wako, 040-21521) at 150 ng / ml for 5 or 10 days to induce cellular senescence by DNA damage. Replicational senescence: - Late-passed (>70 divisions) mouse MSCs were used as senescent cells, and early-passed (<30 divisions) mouse MSCs were used as a control.
[0078] Mouse experiments: C57BL / 6J mice: Purchased from CREA Japan. Whole-body Rubicon knockout mice (C57BL / 6 background): Previously prepared (Reference 22). Rearing conditions: Reared in box cages. Reared under a 12-hour light-dark cycle. Feeded a normal fat diet (MF; Oriental Yeast Co., Ltd.). Room temperature: 23±1.5°C, humidity: 45±15%. Age of mice used: 4 months old (14-16 weeks old), 8 months old (30-32 weeks old), 18 months old (70-72 weeks old). All mice were male.
[0079] Reagents and Antibodies for Western Blotting (WB): Antibodies and Dilution Ratios - CD63: D263-3 (MBL Life Science; 1:5,000), ab134045 (Abcam; 1:2,000) - Flotillin-1: 610821 (BD Biosciences; 1:10,000) - ALIX: 634502 (BioLegend; 1:1,000) - Calnexin: HPA009433 (Sigma-Aldrich; 1:1,000) - Rubicon: 8465 (Cell Signaling Technology; 1:2,000) - α-Tubulin: PM054 (MBL Life Science; 1:20,000) ・WIPI2: SAB4200400 (Sigma-Aldrich; 1:2,000) ・HRS: GTX101718 (GeneTex; 1:1,000)・VPS4: SAB4200025 (Sigma-Aldrich; 1:1,000) ・GFP: 2555 (Cell Signaling Technology; 1:1,000) ・p21: ab109199 (Abcam; 1:1,000)・γH2AX: ab2893 (Abcam; 1:1,000) ・p16INK4a: 11104 (IBL; 1 μg / mL) ・LC3:PM036 (MBL Life Science; 1:2,000) ・Atg12:2011S (Cell Signaling Technology; 1:1,000)・FIP200: 17250-1-AP (Proteintech; 1:1,000) ・Atg2A: PD041 (MBL Life Science; 1:1,000)・Atg2B: HPA019665 (Sigma-Aldrich; 1:1,000) ・Atg14: 96752S (Cell Signaling Technology; 1:1,000) ・Beclin-1:3738S (Cell Signaling Technology; 1:1,000) ・UVRAG:M160-3 (MBL Life Science; 1:2,000) ・ATG16L1:8089 (Cell Signaling Technology; 1:1,000) ・PIK3C3 (Vps34): 3811 (Cell Signaling Technology;1:1,000) ・WIPI1: W4769 (Sigma-Aldrich; 1:1,000) ・WIPI3: PA5-50864 (Thermo Fisher Scientific; 1:1,000)・WIPI4:19194-1-AP (Proteintech; 1:1,000) ・β-Actin: M177-3 (MBL Life Science; 1:2,000) ・FLAG tag: F1804 (Sigma-Aldrich; 1:5,000)・HA tag: 12158167001 (Roche; 1:3,000) • CHMP4B: 13683-1-AP (Proteintech; 1:1,000) • TSG101: 612696 (BD Biosciences; 1:1,000) • EGFR: 20-ES04 (Fitzgerald; 1:1,000) HRP-conjugated secondary antibodies (for WB): • Anti-rabbit IgG: 111-035-003 (Jackson ImmunoResearch; 1:5,000) • Anti-rat IgG: 112-035-003 (Jackson ImmunoResearch; 1:5,000) • Anti-mouse IgG: 115-035-003 (Jackson Immunofluorescence (IF) antibodies and dilution ratios: CD63: D263-3 (MBL; 1:500), 556019 (BD; 1:1,000) LAMP1: 553792 (BD Biosciences; 1:1,000) WIPI2: SAB4200400 (Sigma-Aldrich; 1:500) WIPI1: W4769 (Sigma-Aldrich; 1:200) WIPI3: PA5-50864 (Thermo Fisher; 1:200) ALIX: 634502 (BioLegend; 1:200) Fluorescent secondary antibodies (for IF): • Alexa Fluor 488 (anti-mouse IgG; ab150117) • Alexa Fluor 568 (anti-rat IgG; ab175710) • Alexa Fluor 568 (anti-rabbit IgG; ab175695) • Alexa Fluor 568 (anti-mouse IgG; A11004) • Alexa Fluor 647 (anti-rat IgG; ab150167)
[0080] Reagents・Apilimod: MedChemExpress (HY-14644)・Bafilomycin A1: Wako (023-11641)
[0081] Plasmid construction: pcDNA3.1 empty vector: Invitrogen (V79020) pEGFP-hCD63 vector: Addgene (62964) pMRX-IRES-bsr, pMRX-IRES-puro empty vectors: Provided by S. Yamaoka (Tokyo Medical and Dental University) pMRX-puro-ATG16L1 (full length, WD repeat domain deletion): Previously constructed pcDNA3.1-3×FLAG-hRubicon: Previously constructed pMRX-bsr-GFP-mRubicon: Previously constructed
[0082] Novel plasmid: • Mutant 3×FLAG-hRubicon vector: Constructed by in-fusion reaction (Takara Bio). - mCherry-tagged mRubicon: subcloned into pMRX-IRES-bsr - mStrawberry-tagged WIPI2d, GFP-tagged WIPI2a / WIPI2d, mCherry-2×FYVE, GFP-hCD63: subcloned into pMRX-IRES-puro - HA-tagged WIPI2a / b / c / d, hnRNPA1 / A2 / B1: subcloned into pcDNA3.1 - GFP-VPS4 and GFP-Rab5 were also subcloned into pcDNA3.1, and mutations were introduced into VPS4E228Q and Rab5Q79L respectively (using in-fusion reaction) miRNA vector: pCX-bG-mmu-miR-26a, pCX-bG-mmu-miR-486a: After PCR amplification from mouse genomic DNA, cloning to pCX-bG vectors.
[0083] Other: - Genetic retrovirus production: As previously reported (Reference 89) - Selection of stable cell lines: Selected with blastosidine (10 μg / ml) or pudiomycin (1.5 μg / ml) - Transfection: Lipofectamine 2000 (Thermo Fisher Scientific) was used.
[0084] RNA Interference (RNAi) ・A list of siRNAs used is provided in Supplementary Table 4. ・siRNA double-stranded oligonucleotides: ・Synthesized or purchased by Sigma-Aldrich. ・ON-TARGETplus SMARTpool siRNA used in RNAi screening (Fig. 3a and Fig. 12a) was purchased from Dharmacon. ・Silencer siRNAs were purchased from Thermo Fisher Scientific. ・siRNA transfection was performed on hMSCs or HEK293T cells using Lipofectamine RNAiMAX (Thermo Fisher Scientific). ・Experiments were performed 48 hours after transfection.
[0085] RNA Sequencing (RNA-seq) - Library preparation and sequencing were handled by BGI. - Small RNAs of 18-30 nucleotides were separated by gel electrophoresis. - Library preparation was done using the MGIEasy Small RNA Library Prep Kit (MGI). - Library quality and quantity were confirmed at each step by capillary electrophoresis using an Agilent Bioanalyzer. - Sequencing was performed using a DNBSEC-G400 instrument and combinatorial probe anchor sequencing technology.
[0086] Western blotting: Cells were lysed on ice with the following lysis buffers: 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA; 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS; 1 mM PMSF, protease inhibitor mixture. After centrifugation (20,380 g, 15 minutes), the protein concentration of the supernatant was measured by BCA method. Sample buffer: Non-reducing conditions (for CD63 detection); Reducing conditions (for other protein detection; containing DTT). After separation by SDS-PAGE, the cells were transferred to a PVDF membrane. After staining with Ponceau S, the cells were blocked with 3% skim milk TBS-T for 30 minutes. - Primary antibody (in 3% skim milk TBS-T) was incubated overnight at 4°C. - After incubation for 1 hour with HRP-conjugated secondary antibody, detection was performed. - Luminescence detection reagents: Immobilon Forte Western HRP substrate (Merck), ImmunoStar LD (FUJIFILM Wako). - Images were acquired using ChemiDoc Touch Imaging System (Bio-Rad).
[0087] Exosome Isolation: Isolation from cell culture supernatant: • MEF and RPE-1 cells were cultured in DMEM with FBS, with 10% exosome removal. • MSCs were cultured in serum-free medium STK2 (TWOCELLS). • After centrifugation of the supernatant, exosomes were recovered by ultracentrifugation (110,000 g, using a TLA-55 rotor). • After recovery, the exosomes were washed with PBS and dissolved in sample buffer for immunoblotting.
[0088] Isolation from mouse serum: - ExoQuick reagent (System Biosciences) and TLA120.1 rotor were used. - Albumin levels in serum fractions were measured using QuantiChrome BCG Albumin Assay Kit (BioAssay Systems).
[0089] Exosome isolation for NTA: MagCapture Exosome Isolation Kit PS Ver. 2 (FUJIFILM Wako) was used.
[0090] Notes during comparative experiments: - Exosomes were collected from the same amount of culture medium and the same number of cells. - Multiple markers (e.g., CD63, ALIX) were detected in the exosome fraction, and it was confirmed that organelle markers were not included. Analysis of exosome density and particle size distribution: - Analysis was performed using a NanoSight LM10-HS instrument and NTA2.3 software (Malvern Panalogical).
[0091] Immunofluorescence staining: Cells were fixed with 4% paraformaldehyde (Nacalai Tesque) at room temperature for 20 minutes. Cells were permeabilized with 50 μg / mL digitonin in PBS at room temperature for 10 minutes. Cells were blocked with 0.1% gelatin PBS for 30 minutes. Cells were incubated with primary antibody at room temperature for 60 minutes. Cells were incubated with fluorescently labeled secondary antibody at room temperature for 40 minutes. Finally, cells were mounted using VECTASHIELD Antifade Mounting Medium with DAPI (VECTOR Laboratories). Images were acquired using an FV3000 confocal laser scanning microscope (Olympus) and FV31S-SW software (Ver. 2.3.1.163).
[0092] Gel filtration: MEF or hMSC cells were cultured in a 15 cm dish and washed with PBS after harvesting. The cells were then lysed in the following buffers at 4°C for 15 minutes: 20 mM HEPES-KOH (pH 7.5), 150 mM NaCl, 1 mM MgCl. 20.2% Triton X-100 1 mM PMSF Pepstatin (2 μg / mL) Protease inhibitor cocktail (100 μg / mL) - After dissolution, clarification was performed by ultracentrifugation (100,000 g, 4°C, 10 minutes) + filtration with a 0.2 μm filter. - The clarified sample (250–400 μL) + molecular weight marker (10–30 μL) was loaded onto a Superdex 200 Increase 10 / 300 column (Cytiva). - Buffer: 20 mM HEPES-KOH (pH 7.5), 150 mM NaCl, 1 mM MgCl 2 - Flow rate: 0.4 mL / min, fractionated into 0.2 mL increments. - Fractionated samples were analyzed by Western blotting.
[0093] Immunoprecipitation and mass spectrometry (IP-MS) using MEF. Crosslinking & cell lysis - Stable expression MEF was treated with **±apilimod** for 1 hour, then crosslinked with 0.1% formaldehyde for 10 minutes. Crosslinking was stopped with 100 mM glycine (4 minutes). After washing with HEPES-saline, the cells were thawed on ice with the following HEPES-RIPA buffer: 20 mM HEPES-NaOH (pH 7.5), 150 mM NaCl, 1 mM EGTA, 1 mM MgCl 2 A mixture of 0.25% deoxycholic acid, 0.05% SDS, 1% NP-40 benzonase nuclease, 0.2% PhosSTOP, and a protease inhibitor was added. After sonication, the mixture was centrifuged at 20,380 g, 4°C, for 15 minutes.
[0094] GFP trap precipitation & digestion: The supernatant was immunoprecipitated at 4°C for 2 hours using GFP-Trap magnetic beads (ChromoTek). After washing, the supernatant was digested overnight at 37°C with trypsin / Lys-C mixed enzyme (Promega). The digested products were reduced and alkylated, then desalted with GL-Tip SDB. After drying the eluate, it was redissolved in 0.1% trifluoroacetic acid + 3% acetonitrile.
[0095] Mass Spectrometry (LC-MS / MS) • LC-MS / MS analysis was performed using an EASY-nLC 1200 UHPLC + Orbittrap Fusion (Thermo Fisher Scientific). • A C18 reverse-phase column (75 μm × 150 mm; Nikkyo Technos) was used: • 0-100 minutes: ACN concentration gradient from 4-32% • Then increased to 80% ACN and held for 10 minutes • Mass spectrometry conditions: MS1 resolution: 120,000 Mass range: 375-1500 m / z Data-dependent acquisition mode (maximum 3-second cycle) MS2 acquired with a linear ion trap HCD collision energy 30 Dynamic exclusion 20 seconds
[0096] Data Analysis: The data was analyzed against the SwissProt mouse database using Proteome Discoverer 2.5 (Sequest HT engine). Search parameters: Digestive enzyme: Trypsin (maximum 2 misclevage) Precursor mass error: 10 ppm Fragment mass error: 0.6 Da Modifications: Cysteine carbamide methylation (fixed), N-terminal acetylation, methionine oxidation (variable) Filtering was performed with 1% peptide FDR (using Percolator). Label-free quantification (LFQ) was performed using a Precursor Ions Quantifier node. Total amount normalization was performed between samples. As a fixed modification, cysteine carbamide methylation was set. - Variable modifications were defined as acetylation of the protein N-terminus and oxidation of methionine residues. - Peptide identification results were filtered using a Percolator node to a false discovery rate (FDR) of 1% or less. - Label-free quantification (LFQ) was performed using a Precursor Ions Quantifier node based on the intensity of precursor ions. - Quantitative data normalization was performed for each sample so that the total abundance value of all peptides was the same.
[0097] Immunoprecipitation and Mass Spectrometry (IP-MS) using HeLa Kyoto Cells Sample Preparation: HeLa Kyoto cells transiently expressing a specified plasmid were cultured in a 10 cm dish. Starvation treatment with Earle's Balanced Salt Solution (EBSS) was performed as needed. Protein Treatment: Proteins bound to beads were reduced with 10 mM TCEP and alkylated with 20 mM iodoacetamide. Sample, methanol, chloroform, and water (1:4:1:3, v / v / v / v) were added to the protein and centrifuged at 14,000 g, 30°C, for 5 minutes, and the layers were separated. Four times the amount of methanol was added to the organic layer and centrifuged at 21,880 g, 30°C, for 15 minutes, and the precipitate was collected. - The protein was dissolved in 50 μL of 9 M urea, and the urea concentration was diluted to less than 1 M with 50 mM ammonium carbonate. Protein digestion and mass spectrometry - 200 ng of Trypsin Gold (Promega) was added, and digestion was carried out at 30°C for 17 hours. - After digestion, the solution was acidified with 1% trifluoroacetic acid and desalted using SPEC-TIP (Nikkyo Technos). - The eluate was dried and redissolved in 1% trifluoroacetic acid + 2% acetonitrile. LC-MS / MS analysis - An UltiMate 3000 UHPLC + Q Exactive Plus mass spectrometer (Thermo Fisher) was used. - Connected via DreamSpray ion source. - Data-dependent acquisition was performed using the top 10 method (DDA mode). Measurement conditions: MS1: Resolution 70,000, AGC target 1 x 10 6 Mass range 300-1500 m / z MS2 (HCD method): Resolution 17,500, AGC target 2×10 5Separation window 1.6 m / z, maximum injection time 100 ms, collision energy 27. Dynamic exclusion: 20 seconds. Data analysis - Database: SwissProt (Homo sapiens, 2017 edition) - Search engine: Sequest HT and Mascot (Proteome Discoverer 2.2) - Search parameters: Trypsin digestion (maximum misclevage 3), Precursor mass error 10 ppm, Fragment mass error 0.02 Da. Fixed modification: Carbamide methylation of cysteine. Variable modification: Protein N-terminal acetylation, methionine oxidation, deamidation of asparagine and glutamine, phosphorylation of serine, threonine, and tyrosine. Peptides and proteins were filtered with an FDR of ≤1%. Label-free quantification was performed using a Precursor Ions Quantifier node, and normalized by total peptide amount.
[0098] Co-immunoprecipitation: HEK293T or HeLa Kyoto cells were expressed with the specified tagged protein. Cells were washed twice with PBS and then lysed with M-PER extraction reagent (Thermo Fisher) + inhibitor. After centrifugation at 15,000 g for 10 minutes, the soluble fraction was collected. Anti-FLAG magnetic beads (Sigma-Aldrich) or anti-HA magnetic beads (Thermo Fisher) were rotated and incubated at 4°C for 2 hours. The beads were washed four times with TBS-T. GFP trap assay: Cultured cells were crosslinked and then lysed and sonicated according to the method used in MEF. - The supernatant was incubated overnight at 4°C with GFP-Trap agarose beads (ChromoTek) and washed six times. - After elution with SDS buffer, the solution was heated at 90°C for 5 minutes and immunoblot analysis was performed.
[0099] Electron Microscopy: Cells were fixed with 2.5% glutaraldehyde (Wako) and 2% osmium tetroxide. They were embedded in Quetol-812 resin (Nisshin EM). Ultrathin sections of 80 nm were prepared using an Ultracut E machine (Reichert-Jung). After uranyl acetate and lead staining, the sections were observed using a transmission electron microscope (HT7800; Hitachi).
[0100] Immunoelectron microscopy: Cells were cultured on polystyrene coverslips (Cell Desk; Sumitomo Bakelite). Cells were fixed in 4% formaldehyde (0.1 M phosphate buffer (PB), pH 7.4) at room temperature for 1 hour. Cells were washed three times for 5 minutes each with PB containing 4% sucrose. Cells were permeabilized for 30 minutes with PB containing 0.25% saponin. Cells were blocked with PB containing 10% BSA + 10% normal goat serum + 0.1% fish gelatin. Cells were primary stained overnight at 4°C with anti-GFP antibody (GF090R; Nacalai Tesque) at a 1:200 dilution. Cells were secondary stained at room temperature for 2 hours with gold particle-labeled secondary antibody (1.4 nm nanogold Fab'; Nanoprobes) at a 1:400 dilution. - Gold enhancement (GoldEnhance EM kit; Nanoprobes) was performed for 5 minutes. - Fixation was performed with 1% osmium tetroxide + 1.5% potassium ferrocyanide after 1 hour. - After dehydration with ethanol series, the samples were embedded in epoxy resin (Quetol-812). - 80 nm ultrathin sections were prepared and stained with uranyl acetate + lead. - Observation was performed using a transmission electron microscope (JEM-1400Plus; JEOL) (80 kV, CCD camera: Veleta 2k×2k).
[0101] Isolation of primary AD-MSCs: • Epididymal white adipose tissue was dissociated with Krebs-Ringer bicarbonate HEPES buffer (components listed). • After centrifugation, collagenase (3 mg / mL) was added to the supernatant, and the mixture was shaken at 37°C for 45 minutes. • After filtration with a 100 μm cell strainer, the mixture was centrifuged again to separate it from mature adipocytes. • After three washes, the cells were cultured in MSC Growth Medium 2 (PromoCell).
[0102] SA-β-gal staining: • Senescence Cells Histochemical Staining Kit (Sigma-Aldrich) was used. • Senescence-induced cells on collagen-coated coverslips were fixed with fixative at room temperature for 7 minutes. Washed three times with PBS. Stained at 37°C with CO2. 2 None, stained for 19 hours. Observed using a BX53 microscope (Olympus) + cellSense software.
[0103] RNA Analysis: mRNA analysis - Total RNA extraction was performed from IMR90 cells using ISOGEN II (Japan Gene Research Institute). - Reverse transcription was performed using 1 μg RNA with iScript cDNA Synthesis Kit (Bio-Rad). - Quantitative PCR was performed using Power SYBR Green PCR Master Mix (Thermo Fisher). - Target genes and primers: EZH2, FOXO1, GAPDH, Rnu6 - Internal control: GAPDH
[0104] miRNA analysis: 10ng RNA was reverse transcribed using the TaqMan Advanced miRNA cDNA Synthesis Kit. TaqMan Fast Advanced Master Mix and various miRNA assays were used. Internal control: Rnu6
[0105] RNA-seq data analysis (Processing of RNA-seq data) • Read trimming and filtering were performed using SOAPnuke. • Alignment to the reference genome was performed using Bowtie2 (ver. 2.2.9). • Small RNA expression levels were quantified using unique molecular identifiers (UMI). • Differential gene expression analysis was performed using DEGseq (ver. 1.30.0) with a Q value < 0.001. • GO analysis and KEGG analysis were performed using Dr. Tom system (BGI). Q value < 0.005, or log 10(Q value) > 2.5 The following tools were used in combination for miRNA target prediction: miRanda (ver. 3.3a), RNAhybrid (ver. 0.1), TargetScan (ver. 7.1)
[0106] Image analysis: Protein levels in immunoblots, and the filling rate and number of CD63 dots in endosomes decorated with GFP-Rubicon or GFP-Rab5Q79L were analyzed using Fiji (ImageJ version 2.9.0 / 1.53t).
[0107] Statistical Analysis and Reproducibility: Statistical analysis was performed using GraphPad Prism 9 software. Statistical methods: Two-group comparison: Two-tailed Student t-test. Multiple-group comparison: One-way or two-way ANOVA → Multiple comparison correction using Dunnett or Tukey method. Data notation: Data obtained from biologically independent experiments or samples. Data is expressed as mean ± standard error (SEM). Sample size (n): Determined considering data collection cost and statistical power. Data exclusion criteria: Only experiments that failed due to technical errors were excluded. Experimental reproducibility: All experiments were independently repeated multiple times to confirm reproducibility. Details are provided in each figure caption. - Assignment to experimental groups: Animals and cultured cells were randomly assigned to experimental groups. - Blinding: In Western blotting, blinding was not performed because it was necessary to arrange the samples based on processing information. In immunofluorescence imaging, cell selection was based on a channel different from the channel used for quantification (e.g., DAPI staining). In NTA (nanoparticle tracking analysis), the analysis was performed with sample information concealed.
[0108] [RNAi screening identified Rubicon, which positively regulates exosome secretion] To investigate whether the entire autophagy pathway is necessary for exosome secretion, or whether some specific autophagy factors are sufficient, we first performed RNA interference (RNAi) screening for autophagy-related factors (see Figure 8a).
[0109] In human mesenchymal stem cells (hMSCs), the ATG gene and Rubicon were knocked down, and exosomes were collected from the culture supernatant and performed Western blotting. This RNAi screening revealed that knockdown of ULK1, ATG5, and Rubicon reduced the levels of exosome markers such as CD63 and Flotillin-1 (see Figures 2a, b, and 8b). On the other hand, knockdown of other genes did not show similar effects. Furthermore, in Atg5 knockout (KO) mouse embryonic fibroblasts (MEFs), the levels of CD63 and Flotillin-1 in the exosome fraction were also reduced (see Figures 8c, d).
[0110] [WIPI2 interacts with Rubicon and promotes exosome secretion] To investigate how Rubicon regulates exosome secretion, we attempted to identify partners that interact with Rubicon during exosome biosynthesis. Using immunoprecipitation and mass spectrometry, we identified 79 candidate proteins that may interact with Rubicon in HeLa Kyoto cells. RNA interference (RNAi) screening was performed on these 79 candidate genes (Figure 8a), and it was found that knockdown of 16 of these genes reduced the amount of CD63 in exosomes to less than a quarter of the control level (Figure 3a, and Figures 12a-c). Our previous results had shown that endosomal PI3P plays an important role in exosome secretion (Figure 10c, e, g, h), but these 16 candidate genes did not include PIK3C3 or PIK3R4. Therefore, we re-evaluated the factors involved in the production of endosomal PI3P, and found that in experiments using siPIK3C3 #2, which has high knockdown efficiency, the expression of exosome markers was significantly reduced, indicating that PIK3C3 is essential for exosome secretion (Figure 12d-f). To further narrow down the candidates, we used Apilimod (a compound that promotes exosome biosynthesis) to investigate the interaction partners (interactome) of Rubicon in mouse embryonic fibroblasts (MEFs), and found that WIPI2 strongly co-immunoprecipitated with Rubicon (Figure 3b, Figure 12b, c). This was consistent with the results of RNAi screening, and knockdown or knockout of WIPI2 (or Wipi2) suppressed exosome secretion in both Western blotting and nanoparticle tracking analysis (NTA) (Figure 3c-h). This indicates that WIPI2 is necessary for exosome secretion. WIPI2 is a member of the WIPI family of proteins, which is a mammalian homolog of yeast Atg18. This family has a β-propeller structure (PROPPIN) that binds to polyphosphoinositides and is known to act as an effector that binds to PI3P and regulates autophagosome formation.While the functions of the WIPI family in autophagy are well-studied, their involvement in exosome secretion remains largely unknown. Therefore, we investigated whether other WIPI family proteins are also involved in exosome secretion. We found that WIPI3, like WIPI2, interacts with Rubicon, and this interaction is enhanced by Apilimod treatment (Figure 3b). Consistent with this result, deficiency of WIPI1 or WIPI4 did not affect exosome secretion, but deficiency of WIPI2 or WIPI3 reduced exosome secretion (Figure 13a-d). From these results, we conclude that WIPI2 and WIPI3 interact with Rubicon and play a role in promoting exosome secretion.
[0111] [Rubicon recruits WIPI2d to endosomes to promote exosome secretion] Next, we investigated how WIPI2 cooperates with Rubicon to regulate exosome secretion. Since multiple isoforms of WIPI2 are known to exist, we examined the WIPI2 isoform that interacts most strongly with Rubicon and found that WIPI2d binds most strongly to Rubicon (Figure 13e). WIPI2d was localized in the cytoplasm in control cells, but in cells overexpressing Rubicon (Rubicon-OE), it was localized to CD63-positive endosomes (Figure 3i, j). This suggests that Rubicon recruits WIPI2 to endosomes. Furthermore, unlike WIPI1, endogenous WIPI2 and WIPI3 localized to Rubicon-decorated endosomes under Apilimod treatment (Figure 13f, g). This recruitment of WIPI2 to endosomes was also observed in Fip200-deficient cells, demonstrating its independence from autophagy-related pathways such as autophagosome formation, amphisome generation, and autophagic lysosome reformation (Figure 13f). Of the WIPI2 isoforms, WIPI2d was recruited to Rubicon-positive endosomes, while WIPI2a was not (Figure 3k). Consistent with this result, overexpression of WIPI2d increased the levels of CD63 and WIPI2 in exosomes, but no such effect was observed with WIPI2a (Figure 3l, m). These results suggest that only WIPI proteins specifically recruited to Rubicon-adorned endosomes promote exosome biosynthesis. Importantly, under conditions without Rubicon, overexpression of WIPI2d did not increase exosome secretion (Figure 3n, o, Figure 13h). This indicates that Rubicon promotes exosome secretion by recruiting specific WIPI proteins to endosomes.To elucidate the detailed mechanism of this recruitment, a series of mutants were created in which each domain of Rubicon was deleted (N-terminal serine-rich region: SR-N, coiled-coil domain: CCD, C-terminal serine-rich region: SR-C, helix-coil-rich region: HCR, C-terminal homology domain: RHD) (Figure 14a). As a result, the C-terminal deletion mutant (ΔC) and the HCR deletion mutant (ΔHCR) were unable to pull down endogenous WIPI2 and HA-tagged WIPI2d (Figures 14b, c). Furthermore, expression of the ΔC mutant did not rescue the marker deficiency in the exosome fraction (Figures 14d, e). The ΔHCR mutant also did not co-immunoprecipitate with HA-WIPI2d (Figure 14f). In addition, WIPI3 co-immunoprecipitated with wild-type Rubicon but did not bind to the ΔC mutant. This interaction was enhanced by Apilimod treatment (Figure 14g). These results suggest that Rubicon interacts with the WIPI protein via its HCR domain.
[0112] [The Rubicon-WIPI axis is essential for MVB (multivesicular body) formation] Next, we investigated how the Rubicon-WIPI axis controls exosome secretion. Since bafilomycin A1 is known to maximize exosome secretion by inhibiting MVB acidification, we used it to evaluate the maximum amount of exosomes that a cell can produce (= exosome production capacity). Bafilomycin A1 treatment increased exosome secretion in wild-type cells, but this effect was not observed in Rubicon-deficient cells, WIPI2-deficient cells, and WIPI3-deficient cells (Figures 4a, b and 14h, i). Furthermore, double knockdown of WIPI2 and WIPI3 suppressed exosome secretion even more than knockdown of either one (Figure 14h, i). These results indicate that the Rubicon-WIPI axis is necessary for exosome secretion and that there is functional redundancy (complementarity) between WIPI2 and WIPI3. Therefore, we observed MVB formation using cells expressing Rab5Q79L (a constitutively activated Rab5 mutant). Rab5Q79L inhibits endosomal transport and induces the formation of hypertrophied endosomes containing numerous internal vesicles (ILVs). In WIPI2 knockdown cells, the number of CD63-positive ILVs in hypertrophied endosomes was significantly reduced (Figure 4c, d). Furthermore, it is known that Apilimod treatment also promotes MVB formation, and under this treatment, the number of CD63-positive ILVs surrounded by Rubicon-positive endosomes was also reduced in WIPI2-deficient cells (Figure 4e, f). In addition, electron microscopy confirmed that the number of MVBs themselves was reduced in Rubicon-deficient cells (Figure 15a, b). Immunoelectron microscopy also showed that the number of MVBs containing GFP-CD63-labeled ILVs was reduced in Rubicon-deficient cells (Figures 4g, h and 15c). These results clearly indicate that the Rubicon-WIPI axis is essential for MVB formation.
[0113] [WIPI2 recruits ESCRT factors to endosomes in a Rubicon-dependent manner] To further elucidate the regulatory mechanism of MVB formation via the Rubicon-WIPI axis, interactome analysis of WIPI2d was performed, revealing that multiple ESCRT-related proteins, including HRS, ALIX, VPS4B, VTA1, and IST1, interact with WIPI2d (Figure 5a, b, Figure 15d). Since there are some inconsistencies in previous reports regarding which ESCRT factors are involved in exosome biosynthesis, knockdown experiments of ESCRT factors were performed, and knockdown of HRS, ALIX, and VPS4 reduced the expression of exosome markers (Figure 15e). In addition, in hMSCs, knockdown of HRS, ALIX, TSG101, and VPS4 reduced the number of vesicle particles (measured by NTA) (Figure 15f). These results suggest that ESCRT factors interacting with WIPI2d are essential for exosome formation. Since ESCRT factors do not accumulate in MVBs under normal conditions, we visualized ESCRT localization using dominant repressive VPS4 (VPS4-EQ), which inhibits the dissociation of ESCRT components. VPS4-EQ-positive MVBs were reduced in Rubicon-deficient cells (Figure 5c, d, Figure 15g). Furthermore, Rubicon knockout also reduced ALIX accumulation in endosomes under VPS4 knockdown conditions (Figure 5e, f). These observations suggest that Rubicon is necessary for the recruitment of ESCRT to endosomes. Since HRS, a component of the ESCRT-0 complex, plays a role in recruiting downstream ESCRT factors, we investigated whether Rubicon is involved in the endosomal localization of HRS. As a result, knockdown of Rubicon reduced the interaction between HRS and EGFR (an endosomal substrate involved in ILV formation) (Figure 15h). This indicated that the Rubicon-WIPI axis is required for HRS recruitment to endosomes. Importantly, GFP-WIPI2d pulled down HRS in a Rubicon-dependent manner, while the ESCRT protein did not co-immunoprecipitate with Rubicon (Figures 5g and 15i).Furthermore, Rubicon was not detected in the exosome fraction by Western blot analysis (Figure 2c). Overall, these results indicate that Rubicon recruits WIPI2 to endosomes, where WIPI2 collects ESCRT factors and induces ILV formation (Figure 5h).
[0114] [Rubicon is essential for age-dependent exosome secretion] To investigate the in vivo role of the Rubicon-WIPI axis, exosome secretion in Rubicon-deficient (Rubicon-KO) mice was analyzed (Figure 6a). No growth abnormalities affecting exosome secretion were observed in Rubicon-KO mice (Figures 16a, b). When small exosomes (sEVs) were isolated from serum, the number of serum sEVs was significantly reduced in Rubicon-KO mice (Figures 6b, c and 16d). On the other hand, the number of large exosomes (large EVs) was not reduced (Figure 16e). Furthermore, in adipose tissue-derived mesenchymal stem cells (AD-MSCs), the main source of exosomes, exosome production was reduced in Rubicon-KO mice (Figures 6d, e and 16f). Interestingly, our recent research has shown that Rubicon accumulates in multiple tissues and species with aging. Therefore, we hypothesized that age-related Rubicon accumulation promotes exosome secretion. As expected, Rubicon expression was significantly increased in AD-MSCs isolated from aging mice (Figure 16g,h). Consistent with this, blood exosome levels increased in aging wild-type mice, and notably, this increase was suppressed in aging Rubicon-KO mice (Figure 6f-i and Figure 16i). These results suggest that Rubicon is essential for age-dependent exosome secretion in mice. Previous reports have shown that cellular senescence promotes the secretion of small exosomes (EVs) and also increases Rubicon expression. Therefore, we investigated how Rubicon is involved in exosome secretion associated with cellular senescence. Contrary to previous reports, both doxorubicin (DXR)-induced aging and replication-induced aging significantly increased exosome secretion (Figures 6j, k and 16j). This increase was suppressed by Rubicon deficiency (Figures 6j, k). These findings indicate that Rubicon accumulates with age and is a factor that promotes exosome secretion associated with aging and cellular senescence.
[0115] [Rubicon is required for the secretion of senescence-promoting microRNAs (miRNAs)] Previous reports have shown that miRNA packaging in exosomes is mediated by the ESCRT pathway. Therefore, we investigated whether Rubicon and aging affect the miRNA profile in exosomes. To this end, serum exosomes were isolated from the following four groups of mice and small RNA sequencing was performed: young Rubicon wild-type (WT), aged Rubicon WT, young Rubicon knockout (KO), and aged Rubicon KO. As a result, we identified 10 types of miRNAs that increase with age and are regulated in a Rubicon-dependent manner (Figure 7a, b; Table 1). Furthermore, pathway analysis of predicted miRNA target genes showed significant enrichment of pathways related to the cell cycle and lifespan, particularly FoxO signaling, insulin signaling, and mTOR signaling (Figure 6c and Figure 17a). These results suggest that Rubicon is necessary for age-related changes in the exosome miRNA profile, and that these changes are involved in age-related pathways. Given that Rubicon plays a crucial role in exosome release during cellular senescence, we investigated whether these miRNAs regulate cellular senescence in cultured cells. To this end, we evaluated cellular senescence markers in cells overexpressing miRNAs and found that overexpression of miR-26a-5p or miR-486a-5p increased the expression of senescence markers in IMR90 cells (Figures 7d-g and 17b). This result suggests that the expression of miR-26a-5p and miR-486a-5p promotes cellular senescence. In line with this, previous studies have reported that miR-26a-5p and miR-486a-5p target the anti-aging transcription factor FOXO1, which is known to suppress cell proliferation. Other studies have shown that miR-26a-5p targets the histone methyltransferase EZH2 and promotes cellular senescence by inhibiting the function of EZH2, which suppresses p21 expression.In fact, overexpression of miR-26a-5p or miR-486a-5p in IMR90 cells suppressed mRNA levels of EZH2 and FOXO1 (Figure 7h). These results suggest that miR-26a-5p and miR-486a-5p are secreted into serum exosomes in a Rubicon-dependent manner with aging, suppressing the expression of aging-related genes and promoting cellular senescence.
[0116] [Rubicon mediates exosome-mediated senescence-promoting effects] Previous reports have shown that extracellular vesicles (EVs) secreted by senescent cells promote cellular senescence in receptor cells. Therefore, we investigated whether Rubicon-dependent EV secretion is involved in the progression of cellular senescence. For this purpose, we used the method used in previous studies, adding conditioned medium (CM) from senescent-induced donor cells to receptor cells (Figure 17c). As a result, we found that adding CM derived from senescent donor cells to receptor cells significantly increased the number of SA-β-Gal-positive cells (Figure 7i,j). Importantly, this increase was abolished by knockdown of RUBCN (Rubicon) or WIPI2 in the donor cells (Figure 7i,j). Similarly, CM derived from senescent donor cells caused proliferation arrest in human fibroblasts, but this phenotype was restored by removing EVs or knockdown of RUBCN in the donor cells (Figure 7k). The microRNAs that were confirmed to increase with age and in a Rubicon-dependent manner in the examples are listed in the table below.
[0117] [Description of the Figure] Figure 2: RNAi screening revealed that Rubicon promotes exosome secretion. a: Immunoblot results of CD63 and Flot-1 in the exosome fraction when the specified gene was knocked down in hMSCs (human mesenchymal stem cells). The reading amount for each sample was set to half the amount of exosomes recovered from 1 mL of culture medium. exp. indicates exposure. b: Quantitative results of the amount of CD63 in exosomes in hMSCs with the gene shown in a knocked down. n=4 (number of biologically independent experiments). Statistical significance: *P=0.0385 (control vs ULK1), 0.0371 (control vs ATG5), 0.0254 (control vs ATG13), 0.0387 (control vs RUBCN). c: Immunoblot results for specified proteins in exosome fractions and whole cell lysates (WCL) derived from control and Rubicon knockout (KO) MEF (mouse embryonic fibroblasts). Sample loading was set to half the amount recovered per 1 mL of culture medium for exosomes and 6 μg for WCL. d: Quantitative results of CD63, ALIX, and Flot-1 in exosomes obtained in c. n=3 (number of biologically independent experiments). Statistical significance: **P=0.0069; ***P=0.0002; ****P<0.0001. e: Immunoblot results of CD63 and ALIX in exosome fractions derived from control and Rubicon overexpressing MEF. Sample loading was set to half the amount of exosomes recovered from 1 mL of culture medium. f: Quantitative results of CD63 and ALIX amounts in exosomes from e. n=4 (number of biologically independent experiments). Statistical significance: *P=0.0380 (CD63), 0.0164 (ALIX). g: Nanoparticle tracking analysis (NTA) of extracellular vesicles (EVs) purified using PS affinity magnetic resin (PS-affinity kit) from control or Rubicon KO MEF. h: Quantitative results of total particle concentration of small extracellular vesicles (sEVs) measured in g. n=6 (number of biologically independent experiments). Statistical significance: ****P<0.0001.i: Immunofluorescence image of MEFs stably expressing GFP-Rubicon treated with 0.5 μM apilimod for 1 hour, then stained for CD63 (magenta) and DAPI (blue). Scale bar = 50 μm. Biologically independent experiments were repeated 3 times with similar results obtained. Statistical analysis: • One-way ANOVA + Dunnett's test was used for b. • Student's t-test (two-sided) between two groups was used for d, f, h. Raw data: • Unprocessed blots for a, c, e, and numerical data for b, d, f-h are provided as source data.
[0118] Figure 3: WIPI2 interacts with Rubicon and is essential for exosome secretion. a: Quantification results of CD63 levels in exosomes in hMSCs (human mesenchymal stem cells) with knockdown of the genes shown in Extended Data Figure 4a and control hMSCs. n=2 (biologically independent experiments). The loading amount of each sample was set to half the amount of exosomes recovered from 1 mL of culture medium. b: Label-free quantification (LC-MS / MS analysis) of Rubicon-interacting proteins. Dots represent 828 identified and quantified proteins. Analysis was performed from cell fractions immunoprecipitated using anti-GFP nanobodies. Control or GFP-Rubicon-expressing MEFs (mouse embryonic fibroblasts) were treated for 1 hour in the presence of 0.5 μM apilimod or left untreated. The x-axis represents the log 2 [fold change] (apilimod / mock), the y-axis represents the log 2[fold change] (GFP-Rubicon / control). Rubicon and the WIPI family (WIPI2, WIPI3, etc.) are shown as red dots. c: Nanoparticle tracking analysis (NTA) of extracellular vesicles (EVs) purified from specified cells. d: Quantification of the total number of particles in extracellular vesicles based on c. n=5 (biologically independent experiments). **P=0.0015. e: Immunoblot results of specified proteins in exosome fractions and whole cell lysates (WCL) from control and WIPI2 knockdown hMSCs. Sample loading was set to half per 1 mL of culture medium for exosomes and 6 μg for WCL. f: Quantification of CD63 and ALIX levels in exosomes in e. n=3 (biologically independent experiments). *P=0.0303; ****P<0.0001. g: Immunoblot results for CD63 and ALIX in exosome fractions and WCLs obtained from control and WIPI2 knockout MEFs. h: Quantification of CD63 and ALIX levels in exosomes in g. n=3 (biologically independent experiments). **P=0.0047; ****P<0.0001. i: Immunofluorescence image including DAPI (blue) staining of MEFs stably expressing mStrawberry-WIPI2d (mSt-WIPI2d; magenta) and stably expressing GFP-Rubicon (green) with and without. Scale bar: Standard image = 50 μm, magnified image = 1 μm. j: Immunofluorescence image of similar MEFs stained with CD63 (cyan) and DAPI (blue). Scale bar same as above. k: DAPI stained image of mCherry-Rubicon-expressing MEFs stably expressing GFP-WIPI2a or GFP-WIPI2d. Scale bar = 50 μm. l: Immunoblot results of the specified protein in exosome fractions and WCLs from control MEFs and MEFs overexpressing GFP-WIPI2. m: Quantification of CD63 levels in exosomes of l. n = 3 (biologically independent experiments). *P = 0.0237 (control vs. WIPI2d overexpression). n: Immunoblot of the specified protein in exosome fractions and WCLs when WIPI2d was stably expressed in control or Rubicon KO MEFs.o: Quantification of CD63 levels in exosomes in n. n=5 (WT), n=3 (Rubicon KO); biologically independent experiments. **P=0.0066. [Statistical analysis method] ・d, f, h: Student t-test (two-sided) between two groups ・m: One-way ANOVA + Dunnett's test ・o: Two-way ANOVA ・NS: Not significant ・WT: wild type ・Untreated blots (e, g, l, n) and numerical data (a, c, d, f, h, m, o) are included in the source data.
[0119] Figure 4: The Rubicon-WIPI axis is essential for MVB formation. a: Immunoblot of CD63 in exosome fractions obtained from control and Rubicon knockout (KO) MEF (mouse embryonic fibroblasts). Treatment conditions: with or without bafilomycin A1 (BafA1) treatment (3 hours treatment). The reading volume for each sample was set to half the amount of exosomes recovered from 1 mL of culture medium. b: Quantification results of CD63 levels in exosomes in a. n=3 (biologically independent experiments). *P=0.0258. c: Immunofluorescence images of CD63 (magenta) and DAPI (blue) after transfection of GFP-Rab5Q79L (constitution-activated Rab5) in HEK293T cells treated with WIPI2 knockdown (siWIPI2) or control (luciferase siRNA). Scale bar = 50 μm. d: Quantification of CD63 filling rate in vacuoles (expanded endosomes) labeled with GFP-Rab5Q79L in experiment c. n=29 (control), 54 (siWIPI2) endosomes, pool of 4 independent experiments. ****P < 0.0001. e: Immunofluorescence images of CD63 (magenta) and DAPI (blue) after stable expression of GFP-Rubicon and appilimod treatment in control and WIPI2-deficient MEFs. Scale bar = 50 μm. f: Quantification of the number of CD63 dots in vacuoles decorated with GFP-Rubicon in experiment e. n=5 (control), 3 (WIPI2 KO); 70 or more Rubicon-decorated endosomes and 20 or more cells analyzed under each condition. *P = 0.0163; **P = 0.0024. g: Immunoelectron microscopy images of cells stably expressing GFP-CD63 in control and Rubicon KO MEF cells (representative examples of MVB structures). Scale bar = 500 nm. h: Violin plot of MVB count per cell in experiment g. n = 33 (WT), 31 (Rubicon KO); data from one independent experiment. Solid line represents the median, dotted line represents the interquartile range.[Statistical Analysis Methods] ・ b: Two-way ANOVA ・ d, f: Student t-test (two-sided) between two groups [Notes] ・ a (untreated blot) and b, d, f, h (numerical data) are provided as source data.
[0120] Figure 5: WIPI2 interacts with multiple ESCRT components in a Rubicon-dependent manner. a: Volcano plot of label-free quantification of WIPI2d interacting proteins. Dots indicate proteins identified and quantified by LC-MS / MS analysis of immunoprecipitated samples from control or GFP-WIPI2d-expressing MEF (mouse embryonic fibroblasts). Immunoprecipitation was performed using anti-GFP nanobodies. x-axis represents the log between GFP-WIPI2d-expressing cells and control cells. 2 [fold change], the y-axis is obtained from triple measurement (n=3) log 10[P-values] are shown. Red areas indicate significantly increased proteins (FC>2, P<0.05), and green areas indicate significantly decreased proteins (FC<2, P<0.05). b: Immunoprecipitation assay. HEK293T cells were transfected with the specified plasmid for 24 hours, lysed, and then immunoprecipitated with anti-GFP nanobodies. The precipitate was immunoblotted with the specified antibody. n=3 (biologically independent experiments, similar results exist). c: Immunofluorescence images of CD63 (green) and DAPI (blue) in HeLa Kyoto cells transfected with mRFP-VPS4E228Q (RFP-VPS4EQ). Scale bar = 50 μm. d: Left: Violin plot (n=21) showing the number of mRFP-VPS4E228Q-positive endosomes and CD63-positive endosomes (magenta and green dots, respectively) obtained from c. ***P=0.0003. Right: Quantification of the proportion of mRFP-VPS4E228Q and CD63-positive endosomes to the total number of endosomes under each condition. n=3 (more than 20 cells analyzed under each condition). **P=0.0077. e: Immunofluorescence images of ALIX (magenta) and DAPI (blue) of control and Rubicon-deficient HeLa Kyoto cells transfected with siVPS4 and GFP-CD63. Scale bar = 50 μm for standard image, 2 μm for magnified image. f: Top panel: Violin plot showing the number of ALIX-positive and CD63-positive endosomes (magenta and green dots) obtained from e (n=76 (WT), 72 (Rubicon KO)). ***P=0.0008. Bottom panel: Quantification of the proportion of ALIX and CD63-positive endosomes to the total number of endosomes under each condition. n=3 (more than 20 cells analyzed under each condition). *P=0.0108. g: Immunoprecipitation assay. WT or Rubicon KO HeLa cells were transfected with the specified plasmid for 24 hours, followed by cell lysis, immunoprecipitation with anti-GFP nanobodies, and immunoblotting with the specified antibody. n=3 (biologically independent experiments, similar results observed). h: Conceptual diagram (schema) showing how Rubicon, WIPI2, and the ESCRT mechanism function in the MVB formation process. [Statistical analysis] a, d, f: Student's t-test (two-sided) between two groups was used.[Notes] ・The untreated blots for b and g, as well as the numerical data for d, f, and g, are included in the source data.
[0121] Figure 6: Rubicon is required for age-dependent exosome increase in mouse serum. a: Experimental design for sampling serum or primary cells from mice. Serum and white adipose tissue (WAT) were isolated from wild-type (WT) and Rubicon knockout (KO) male mice. Primary AD-MSCs (adipose-derived mesenchymal stem cells) were obtained from WAT by collagenase treatment. b: Top panel: Immunoblot of ALIX and Flot-1 in exosome fractions purified from 15 or 45 μL of serum from 8-month-old WT and Rubicon KO male mice. Bottom panel: Serum albumin levels of control mice. n=3 mice (WT and Rubicon KO). The reading for each sample corresponds to the total amount of exosomes recovered from 15 or 45 μL of serum, respectively. c: Quantitative results of ALIX and Flot-1 levels (normalized by serum albumin level) in exosomes derived from 45 μL serum of b. n=3 (independent mice). **P=0.0018 (ALIX), 0.0028 (Flot-1). d: Immunoblot of ALIX in exosomes purified from the culture supernatant of primary AD-MSCs from 4-month-old WT and Rubicon KO male mice. n=3 (WT), 4 (Rubicon KO). *P<0.05. The reading amount for each sample is half the amount of exosomes per 1 mL of culture medium. e: Quantitative determination of ALIX levels in exosomes of d. n=3 (WT), 4 (Rubicon KO). *P=0.0206. f: Top panel: Immunoblot of ALIX and Flot-1 in exosomes purified from 15 μL of serum from male mice of each genotype at 4 months or 18 months of age. Bottom panel: Serum albumin levels of the control mice. n=3 (4-month WT), 4 (4-month Rubicon KO), 5 (18-month WT), 4 (18-month Rubicon KO). g: Quantification of ALIX levels in exosomes normalized by serum albumin levels based on f. n=3 (4-month WT), 4 (4-month Rubicon KO), 5 (18-month WT), 4 (18-month Rubicon KO). ***P=0.0004. (*M=months of age) h: Nanoparticle tracking analysis (NTA) of extracellular vesicles (EVs) purified from the serum of the control mice. i: Determination of the total number of EV particles at h. n=3 (biologically independent experiment).*P = 0.0158; ****P < 0.0001. j: Immunoblotting of ALIX and Flot-1 in exosome fractions of culture supernatant from primary AD-MSCs (with / without replication senescence) derived from 4-month-old WT and Rubicon KO male mice. n = 3 (biologically independent experiments). The reading volume for each sample was half the amount of exosomes per 1 mL of culture medium. k: Quantification of ALIX and Flot-1 levels in exosomes in j. (R / S = replication senescence) n = 3 (biologically independent experiments). ***P = 0.0002 (WT vs WT R / S), ***P = 0.0003 (WT R / S vs Rubicon KO R / S), ****P < 0.0001. [Statistical Analysis Methods] - c, e: Student t-test (two-sided) between two groups - g, i, k: One-way ANOVA + Dunnett's test [Notes] - Untreated blots for b, d, f, j, and numerical data for c, e, g, h, i, k are provided as source data.
[0122] Figure 7: Rubicon deficiency suppresses age-dependent changes in the serum exosome miRNA profile. a: Diagram showing the procedure for small RNA sequencing of serum exosomes. Exosomes were purified using the PS affinity kit from the serum of 4-month-old WT (young WT), 18-month-old WT (elderly WT), 4-month-old Rubicon KO (young Rubicon KO), and 18-month-old Rubicon KO (elderly Rubicon KO) male mice. n=3 (independent mice). b: Venn diagram. Shows the differential gene expression numbers observed in serum extracellular vesicles in comparison to: Elderly WT vs. Young WT (magenta), Elderly WT vs. Elderly Rubicon KO (orange), and Elderly Rubicon KO vs. Young Rubicon KO (green). n=3 (independent mice). c: Bubble plot of KEGG pathway enrichment analysis. Based on target genes of 10 miRNAs abundant in serum extracellular vesicles obtained in b. x axis is pathway enrichment, y axis is pathway category. Bubble size indicates the number of target genes, and color indicates the corrected q value. d: Immunoblot of p21, γH2AX, and β-actin after transfection of IMR90 cells with specified miRNAs. n=4 (P21 and β-actin), n=3 (γH2AX). Loading amount for each sample was 6 μg. e: Quantification of p21 and γH2AX levels (normalized by β-actin) in d. n=4 (P21), n=3 (γH2AX). *P=0.0381; **P=0.0013 (control vs miR-26a-5p); **P=0.0048 (control vs miR-486-5p); ***P=0.0002. f: Immunoblot of p16 and α-tubulin after transfection of IMR90 cells with the specified miRNA and 15 hours of doxorubicin treatment. n=5. Load amount: 10 μg. g: Quantification of p16 levels (normalized by α-tubulin) in f. n=5. *P=0.0357; **P=0.0044. h: mRNA expression of EZH2 and FOXO1 in IMR90 cells (after transfection of the specified miRNA). n=3. *P=0.0318; ****P<0.0001.i: Representative image of receptor RPE-1 cells treated with conditioned medium and stained with SA-β-gal. Cellular senescence was induced by doxorubicin (DXR) treatment for 5 days, followed by the addition of culture medium. n=5. Scale bar=100μm. j: Quantification of the percentage of SA-β-gal positive cells in i. n=5. *P=0.0316; ***P=0.0001 (Luc 5 days vs RUBCN 5 days); ***P=0.0002 (Luc 10 days vs RUBCN 10 days); ****P<0.0001. [Statistical Analysis Methods] ・e, g, h: One-way ANOVA + Dunnett's test ・j: One-way ANOVA + Tukey's test [Notes] ・Untreated blots for d and f, and numerical data for c, e, g, h, and j are included in the source data. ・Terminology: oEGFR: Epidermal growth factor receptor oEV: Extracellular vesicle oMAPK: Mitogen-activated protein kinase omTOR: Target of rapamycin in mammals oPI3K: Phosphatidylinositol 3-kinase.
[0123] Figure 8: Rubicon promotes exosome biosynthesis independently of the autophagy pathway. (a) Schematic diagram of exosome isolation from the culture supernatant of siRNA-transfected hMSCs (human mesenchymal stem cells). (b) Quantification of Flot-1 levels in exosomes in cells with knockdown of each gene shown in Fig. 1a. Bar graphs show mean ± standard error (SEM) (n=4, independent biological experiments). *p=0.0304 (control vs ULK1), 0.0157 (control vs ATG5), 0.0113 (control vs ATG13), **p=0.0073 (control vs RUBCN). Statistical analysis was performed using one-way ANOVA and Dunnett method. (c) Immunoblotting of each protein in exosome fractions and whole cell lysates (WCL) obtained from control and Atg5 knockout (KO) MEFs. Sample loading amounts were as follows: half the amount of exosome sample obtained from 1 mL of medium, and 6 μg of WCL. (d) Quantification of CD63 and Flot-1 in exosomes in (c). Bar graphs are mean ± SEM. n=3, independent biological experiments. ***p=0.0007, ****p<0.0001 (two-sided t-test). (m) Immunoblotting in exosomes and WCL from wild-type and Rubicon-KO MEFs (empty vector or GFP-Rubicon introduced). (n) Immunoblotting in WCL from control and Rubicon overexpression (OE) MEFs (loading amount 10 μg). The raw blot images (c, m, n) and quantitative data (b, d) are included in Source Data. Biologically independent experiments for (m, n) were repeated twice, yielding similar results.
[0124] Figure 9: Rubicon promotes exosome biosynthesis. (a) Left: Immunoblotting of various proteins in exosome fractions and whole cell lysate (WCL) obtained from control and RUBCN knockdown hMSCs. Right: Representative image of trypan blue staining. Live cells are shown in green, dead cells in red. Scale bar: 200 μm. Sample loading amounts were as follows: half the amount of exosome sample obtained from 1 mL of medium, and 6 μg of WCL. (b) Left: Quantification of the ratio of live cells to total cells in (a). Right: Quantification of CD63 and ALIX levels in exosomes in (a), normalized by the number of live cells. Bar graphs show mean ± standard error (SEM) (n=3, independent biological experiments). ns: no significant difference; *p=0.015, **p=0.0015 (two-tailed t-test). (c) Relative comparison of total cell number in control and RUBCN knockdown hMSCs. Bar graphs show mean ± SEM (n=3, independent biological experiments). ns: no significant difference (two-sided t-test). (d) Left: Ponceau S staining of exosome fractions obtained from control and Rubicon overexpressing MEFs. Right: Representative image of trypan blue staining. Live cells are shown in green, dead cells in red. Scale bar: 200 μm. Sample load: half the amount of exosome sample obtained from 1 mL of medium. (e) Left: Quantification of the ratio of live cells to total cells in (d). Right: Quantification of exosome levels normalized by live cell number using Ponceau S staining in (d). Bar graphs show mean ± SEM (n=4, independent biological experiments). ns: no significant difference; **p=0.0081 (two-sided t-test). The raw immunoblots (a, d) and numerical data (b, c, e) are included in Source Data.
[0125] Figure 10: Apilimod treatment promotes exosome biosynthesis in a Rubicon-dependent manner. (c) Scheme diagram of pharmacological inhibition of PIKFyve. Inhibitor: Apilimod. (e) Immunofluorescence images of CD63 (cyan) and DAPI (blue) after Apilimod treatment of MEFs expressing GFP-Rubicon and mCherry-2×FYVE. Scale bar: 50 μm for standard image, 10 μm for magnified image. (f) Immunofluorescence images of LAMP1 (magenta) and DAPI (blue) after Apilimod treatment of MEFs expressing GFP-CD63. Scale bar: 50 μm. (g) Immunoblotting of various proteins in exosome fractions and whole cell lysates (WCL) obtained from WT and Rubicon-KO MEF under conditions with and without Apirimod. Sample loading volume: half the amount of exosome sample obtained from 1 mL of medium, 6 μg of WCL. (h) Quantification of CD63 levels in exosomes in (g). Bar graphs show mean ± SEM (n=4, independent biological experiments). ns: no significant difference; ****p < 0.0001 (two-way ANOVA). Raw blot (g) and quantitative data (h) are included in Source Data. The independent biological experiments in (e-f) were repeated twice with similar results.
[0126] Figure 11: Neither canonical nor acanthological autophagy pathways are required for exosome secretion. (a) Immunoblotting of various proteins in exosome fractions and whole cell lysates (WCL) obtained from control, Rubicon-KO, and Beclin-1-KO MEFs. Sample loading amount: Half the amount of exosome sample recovered from 1 mL of medium, 6 μg of WCL. (b) Immunoblotting of various proteins in exosome fractions and WCL obtained from control and Uvrag-KO MEFs. Sample loading amount: Half the amount of exosomes in 1 mL of medium, 10 μg of WCL. (c) Quantification of exosome amounts of CD63, Flot-1, and ALIX in (b). Bar graphs show mean ± standard error (SEM) (n=3, independent biological experiments). ns: No significant difference (two-tailed t-test). Experiments (a, d) were performed independently twice, yielding similar results.
[0127] Figure 12: Multiple candidates were identified by RNAi screening of exosome regulatory factors focusing on Rubicon-binding proteins. (a) Immunoblotting of CD63 in the exosome fraction isolated from the culture supernatant of hMSCs with the specified gene knocked down. The loading volume of each sample is half the amount of exosomes from 1 mL of medium. (b) Scheme diagram showing the identification of WIPI2. This is based on interactome analysis of Rubicon-binding factors and RNAi screening for exosome secretion. (c) Unique peptides and total peptide counts that may be involved in exosome regulation obtained from the analysis in (b) (by Rubicon interactome analysis using HeLa Kyoto cells). (d) Immunoblotting of CD63 and ALIX in the exosome fraction isolated from the culture supernatant of hMSCs with the specified gene knocked down. The loading volume of each sample is half the amount of exosomes from 1 mL of medium. (e) Quantification of CD63 and ALIX exosome levels in (d). Bar graphs show mean ± standard error (SEM) (n=3, independent biological experiments). *p = 0.037 (CD63), 0.0232 (ALIX), ****p < 0.0001 (all one-way ANOVA + Dunnett test). (f) Immunoblotting of various proteins in hMSCs with specified gene knockdown. Load amount for each sample was 10 μg. Raw blot images (a, d, f) and quantitative data (e, f) are included in Source Data. The independent biological experiment in (f) was repeated twice with similar results.
[0128] Figure 13: Rubicon recruits WIPI proteins to endosomes, which are necessary for exosome biosynthesis. (a) Immunoblotting of various proteins in exosome fractions and whole cell lysates (WCL) obtained from hMSCs with specified gene knockdown. Loading volume for each sample: half the volume of the exosome sample recovered from 1 mL of medium, 6 μg for WCL. (b) Quantification of CD63 levels in exosomes in (a). Bar graphs show mean ± standard error (SEM) (n=4, independent biological experiments). ns: no significant difference; *p=0.0183 (control vs siWIPI2 #2), 0.0160 (control vs siWIPI3), one-way ANOVA + Dunnett method. (c) Nanoparticle tracking analysis (NTA) of EV purified from the culture supernatant of hMSCs by ultracentrifugation. (d) Quantification of total particle concentration of EV in (c). Bar graphs show mean values (n=5, independent biological experiments). ns: no significant difference; ****p<0.0001 (one-way ANOVA + Dunnett method). (e) Immunoprecipitation assay. HEK293T cells were transfected with the specified plasmid for 24 hours, the cells were lysed, and immunoprecipitation was performed with anti-HA antibody. The precipitate was immunoblotted with the specified antibody. (f) Immunofluorescence images of WIPI2 (magenta) and DAPI (blue) in wild-type or Fip200-KO MEF expressing GFP-Rubicon after Apilimod treatment. Scale bar: standard image 50 μm, magnified image 10 μm. (g) Immunofluorescence images of WIPI1 or WIPI3 (magenta) and DAPI (blue) in GFP-Rubicon-expressing MEFs after Apirimod treatment. Scale bar: standard image 50 μm, magnified image 10 μm. (h) Immunoblotting of proteins in whole cell lysates from wild-type and Rubicon-KO MEFs expressing an empty vector (control) or mStrawberry-WIPI2d plasmid (WIPI2 overexpression). Loading amount for each sample was 6 μg. Raw blot images (a, e, h) and quantitative data (b-e) are included in Source Data. Biological independent experiments (e-h) were repeated twice with similar results.
[0129] Figure 14: The helix-coil rich region (HCR) in Rubicon is required for interaction with WIPI2. (a) Schematic diagram of Rubicon and its truncated mutants. Rubicon FL: 3 x FLAG-Rubicon (1-972), ΔC: 3 x FLAG-Rubicon (1-508), ΔN: Rubicon (509-972), ΔSR-N: 3×FLAG-Rubicon (1-203,448-972), ΔCCD: 3×FLAG-Rubicon (1-504,558-972), ΔSR-C: 3×FLAG-Rubicon (1-566,626-972), ΔHCR: 3×FLAG-Rubicon (1-625, 761-972), ΔRHD: 3×FLAG-Rubicon (1-698). (b) Immunoprecipitation assay. HEK293T cells were transfected with HA-WIPI2d and 3×FLAG (FLAG) or Rubicon mutant plasmids for 24 hours, and immunoprecipitation was performed with anti-FLAG antibody. The precipitate was immunoblotted with the specified antibody. (c) Immunoprecipitation assay. HEK293T cells were transfected with the specified plasmid for 24 hours, immunoprecipitation was performed with anti-FLAG antibody, and then immunoblotting was performed. (d) WT and Rubicon-KO MEF cells were expressed with the specified plasmid, and immunoblotting of the specified protein was performed in the exosome fraction and whole cell lysate (WCL) isolated from the culture supernatant. Loading amount for each sample: half the amount of exosomes from 1 mL of medium, 6 μg for WCL. (e) Quantification of exosome amounts of CD63 and ALIX in (d). Bar graphs show mean values (n=3, independent biological experiments). ns: No significant difference; **p = 0.0011 (WT vs RubiconΔC: CD63), 0.0014 (WT vs empty: ALIX), 0.0014 (WT vs RubiconΔC: ALIX), ***p = 0.0006 (one-way ANOVA + Dunnett test). (f) Immunoprecipitation assay. HEK293T cells were transfected with HA-WIPI2d and Rubicon mutant plasmids for 24 hours (* indicates untransfected cells), followed by immunoprecipitation with anti-HA antibody and immunoblotting. (g) Immunoprecipitation assay.HEK293T cells were transfected with the specified plasmid for 24 hours under conditions with or without Apilimod treatment, followed by immunoprecipitation and immunoblotting with anti-FLAG antibody. (h) Immunoblotting of the specified protein in the exosome fraction and WCL isolated from the culture supernatant was performed under conditions with or without 3 hours of bafilomycin A1 treatment of hMSCs, and with or without the specified gene knocked down. Loading amounts were half the volume of 1 mL of medium for exosomes and 6 μg for WCL. (i) Quantification of the exosome amount of CD63 in (h). The bar graph shows the mean ± standard error (SEM) (n=4, independent biological experiments). ns: No significant difference; **p = 0.0086 (WIPI2 vs WIPI2 + BafA1), 0.0068 (WIPI3 vs WIPI3 + BafA1), 0.0096 (WIPI2 + BafA1 vs WIPI2 + WIPI3 + BafA1), 0.0013 (WIPI3 + BafA1 vs WIPI2 + WIPI3 + BafA1), ****p < 0.0001 (one-way ANOVA + Tukey test). Raw blots (b, c, d, f, g, h) and quantitative data (c, e, g, i) are included in Source Data. Independent experiments for (b, c, f, g) were performed twice, yielding similar results.
[0130] Figure 15: ESCRT machinery interacts with WIPI2 and is required for exosome biosynthesis. (a) Representative electron micrographs of polyvesicular bodies (MVBs) in control and Rubicon-KO MEF. Scale bar: 1 μm. (b) Violin plot showing the number of MVBs per cell shown in (a). WT: 11 cells, Rubicon KO: 35 cells, obtained from two independent biological experiments. Solid line shows median, dotted line shows interquartile range. ***p = 0.0001 (two-sided t-test). (c) Immunoblotting of GFP-CD63 in whole cell lysates (WCL) obtained from control and Rubicon-KO MEF stably expressing GFP-CD63. Loading amount for each sample: 6 μg. (d) Schematic diagram of ESCRT machinery and MVB formation process. Red indicates ESCRT components and related proteins that showed interaction with WIPI2d in Figure 4a. (e) Immunoblotting of various proteins in the exosome fraction and whole cell lysate obtained from hMSCs with the specified gene knocked down. Loading amount: half of 1 mL of medium for exosomes, 6 μg for WCL. (f) Nanoparticle tracking analysis (NTA) of EV purified by ultracentrifugation from the culture supernatant of hMSCs with the specified gene knocked down. (g) Violin plot showing the total number of CD63 dots in the specified cells in Figure 4c (n=21 cells, one independent experiment). The solid line shows the median, and the dotted line shows the interquartile range. ns: No significant difference (two-sided t-test). (h) Immunoprecipitation assay. HEK293T cells were subjected to knockdown of the specified gene and plasmid introduction, and after lysing the cells, immunoprecipitation was performed with anti-FLAG antibody. The precipitate was immunoblotted with the specified antibody. (i) Immunoprecipitation assay. After introducing the specified plasmid into HEK293T cells, immunoprecipitation was performed with anti-FLAG antibody, followed by immunoblotting. Unprocessed blot images (c, e, h, i) and numerical data (b, f, g, h) are included in Source Data. Biologically independent experiments (c, e, h, i) were repeated twice, yielding similar results.
[0131] Figure 16: Rubicon knockout suppresses age-related increase in exosome secretion in vivo. (a) Time course of body weight in male mice of a specified genotype fed a normal diet. WT: n=21, Rubicon-KO: n=21. Bar graphs show mean ± standard error (SEM). (b) Body weight of 18-month-old male mice. WT: n=5, Rubicon-KO: n=4. Bar graphs show mean ± SEM. ns: no significant difference (two-sided t-test). (c) Schematic diagram of the procedure for separating serum-derived exosomes. (d) Serum albumin concentration obtained from WT or Rubicon-KO male mice. n=3 (independent individuals). Bar graphs show mean ± SEM. ns: no significant difference (two-sided t-test). (e) Nanoparticle tracking analysis (NTA) of large extracellular proteins (EVs) purified from serum of 4-month-old or 18-month-old male mice using the PS affinity kit. (f) NTA of EVs purified from primary AD-MSCs derived from 4-month-old WT or Rubicon-KO male mice using ultracentrifugation. (g) Immunoblotting of specified proteins in whole cell lysates (WCL) of primary AD-MSCs derived from 4-month-old or 18-month-old WT or Rubicon-KO male mice. 4-month-old WT: n=3, 4-month-old Rubicon-KO: n=4, 18-month-old WT: n=5, 18-month-old Rubicon-KO: n=4. Loading amount for each sample was 6 μg. (h) Quantification of Rubicon expression levels (α-tubulin normalized) in (g). Bar graphs are mean ± SEM. 4 months old: n=3, 18 months old: n=5. **p=0.0075 (two-tailed t-test). (i) Serum albumin concentration obtained from specified mice. 4 months old WT: n=3, 4 months old Rubicon-KO: n=4, 18 months old WT: n=5, 18 months old Rubicon-KO: n=4. Bar graphs are mean ± SEM. ns: no significant difference (one-way ANOVA + Tukey test). (j) Immunoblotting of specified protein in exosome fraction obtained from specified DXR-treated RPE-1 cells. Sample loading amount was half the amount of exosomes from 1 mL of medium. Raw blots (g, j) and quantitative data (a, b, d, e, f, h, i) are included in Source Data. Biological independent experiment (j) was repeated twice with similar results.
[0132] Figure 17: Rubicon is essential for age-dependent changes in the exosome microRNA profile that promote cellular senescence. (a) Gene Ontology (GO) enrichment analysis of genes targeted by 10 miRNAs that were rich in serum EV in Figure 6b. The X axis shows the -log10 q value in duplicate experiments (n=3). (b) Changes in the expression level of specified miRNAs in specified cells (fold change). The bar graph shows the mean ± standard error (SEM) (n=3, biologically independent experiments). *p=0.0195, **p=0.0031 (two-sided t-test). (c) Scheme diagram of the experiment in which recipient cells were treated with a conditional culture medium (CM) of senescent donor cells. (d-e) Immunoprecipitation assay. HEK293T cells were transfected with the specified plasmid, the cells were lysed, and immunoprecipitation was performed with anti-FLAG antibody. The precipitate was immunoblotted with the specified antibody. (f) Venn diagram. Shows the number of differentially expressed genes (DEGs) in serum EV of 4-month-old young WT and young Rubicon-KO (blue), and 18-month-old aged WT and aged Rubicon-KO (yellow). (g) Immunoprecipitation assay. HEK293T cells were transfected with the specified plasmid, followed by immunoprecipitation with anti-HA antibody and immunoblotting. Raw blots (d, e, g) and quantitative data (a, c) are included in Source Data. Biological independent experiments of (d, e, g) were performed twice and similar results were obtained.
Claims
1. A method for evaluating the amount or activity of Rubicon, characterized by comprising a step of detecting age-related miRNAs in a sample.
2. The method for evaluating the amount or activity of Rubicon according to claim 1, wherein the miRNA associated with aging is a miRNA that increases with age.
3. The method for evaluating the amount or activity of Rubicon according to claim 1, wherein the miRNA associated with aging is a miRNA whose secretion to the extracellular space by exosomes increases with age.
4. The method for evaluating the amount or activity of Rubicon according to claim 1, wherein the miRNA associated with aging is a miRNA that targets FOXO-1 or EZH2.
5. The age-related miRNAs are human mature miRNAs (hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486), and mouse mature miRNAs (mmu-miR-26a-5p, mmu- A method for evaluating the amount or activity of Rubicon according to claim 1, wherein one or more are selected from the group consisting of miR-10a-5p, mmu-miR-15b-5p, mmu-miR-30e-3p, mmu-miR-93-5p, mmu-miR-191-5p, mmu-miR-328-3p, mmu-miR-486a-5p, mmu-miR-486b-5p, and mmu-miR-1198-5p.
6. The method for evaluating the amount or activity of Rubicon according to claim 1, wherein the sample is blood, serum, urine, or body fluid.
7. A method for evaluating autophagy activity or the degree of aging, characterized by comprising a step of detecting age-related miRNAs in a sample.
8. The method for evaluating autophagy activity or the degree of aging according to claim 7, wherein the age-related miRNA is a miRNA that increases with age.
9. The method for evaluating autophagy activity or the degree of aging according to claim 7, wherein the age-related miRNA is a miRNA whose secretion to the extracellular space by exosomes increases with age.
10. The method for evaluating autophagy activity or the progression of aging according to claim 7, wherein the miRNA associated with aging is a miRNA that targets FOXO-1 or EZH2.
11. The aging-related miRNAs are human mature miRNAs (hsa-miR-26a-5p, hsa-miR-10a-5p, hsa-miR-15b-5p, hsa-miR-30e-3p, hsa-miR-93-5p, hsa-miR-191-5p, hsa-miR-328-3p, and hsa-miR-486), and mouse mature miRNAs (mmu-miR-26a-5p, mmu-mi The method for evaluating autophagy activity or the degree of aging according to claim 7, wherein one or more are selected from the group consisting of R-10a-5p, mmu-miR-15b-5p, mmu-miR-30e-3p, mmu-miR-93-5p, mmu-miR-191-5p, mmu-miR-328-3p, mmu-miR-486a-5p, mmu-miR-486b-5p, and mmu-miR-1198-5p.
12. The method for evaluating autophagy activity or the progression of aging according to claim 7, wherein the sample is blood, serum, or urine.
